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ABSTRACT
Colorectal cancer (CRC) is one of the leading causes of death in developed countries. Although, 
a small fraction of cancers are caused by inherited genetic predisposition most of the CRCs are 
sporadic. In CRC, cancer risk is associated with lifestyle factors and aging. Even in dominantly 
inherited CRC predisposition such as in Lynch syndrome (LS), which is linked to germline mu-
tations in the mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2, cancer develops 
as a result of accumulation of genetic and epigenetic changes. After diagnosing an LS family, 
to be able to offer contiguous pre-symptomatic surveillance and predictive gene counseling to 
mutation carriers in a family, the pathogenicity assessment of a mutation is needed. Dependent 
on the type and the site of a germline mutation, inherited cancer risk may vary from high to 
low and especially in the latter case cancer risk may be strongly affected by lifestyle factors 
such as diet. Epidemiological studies on humans and previous studies on mice have shown 
that especially a Western-style diet (WD) may predispose colon mucosa to CRC. However, the 
mechanisms, which mediate the effects of diet on tumorigenesis are largely unknown.
Since both genetic and lifestyle factors have been shown to predispose to cancer, this the-
sis analyzed biochemical defects caused by inherited MMR gene mutations and Western diet 
exposure. Different MMR gene mutations may compromise MMR function through various 
biochemical defects. Here, we studied 18 inherited non-truncating mutations in MSH2, the 
second most frequently mutated gene among Lynch syndrome patients. We assessed protein 
stability, DNA binding, and ATP mediated DNA release abilities of the MSH2 variants. The 
majority of variants in the amino terminal region including the connector and lever domains 
p.V161D, p.G162R, p.G164R, p.L173P, p.L187P, p.C333Y, p.D603N) affected protein stabil-
ity. Variations in the ATPase domain (p.A636P, p.G674A, p.C697F, p.I745-I746del, p.E749K) 
totally abolished either mismatch binding or release. Four protein variants (p.T33P, p.A272 V, 
p.G322D, p.V923E) expressed slightly reduced mismatch binding and/or release efficiencies 
compared to wild-type (WT) MSH2 protein, while two variants (p.N127S, p.A834T) were in-
distinguishable from WT.
To define the effects of Western-style diet, we analyzed protein expression changes in histolog-
ically normal colon mucosa of wild type (Mlh1+/+) and CRC predisposed mice (Mlh1+/-) after 
a long-term feeding experiment with WD and AIN-93G control diet. Using network analysis 
and data mining we also determined which of the affected proteins might be putative play-
ers in early CRC development. Our results pinpoint changes in a complex protein interaction 
network involved in ATP synthesis coupled proton transport, oxidoreduction coenzyme and 
nicotinamide nucleotide metabolic processes, which are important in the generation of reactive 
oxygen species (ROS) and cellular protection against ROS toxicity. Additionally, we detected 
SELENBP1 and LGALS4, which are implied in neoplastic processes. 
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Our studies show that mutations in the MMR gene affect the biochemistry of MMR, can have 
an effect on the phenotype of the mutation carriers and in the latest study suggest that the high 
sensitivity to Western diet may be linked to haplo-insufficiency caused by a loss of function 
mutation in the Mlh1+/- mice. 
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INTRODUCTION
Cancer is one of the leading causes of deaths worldwide (www.who.int), and colorectal cancer 
(CRC), which has a five-year prevalence of 8.9% in the United States and 14.3% in Europe 
(Finland 10.7%) (http://globocan.iarc.fr) is the third most common diagnosed cancer (www.
cancer.org). The lifetime risk of developing CRC is about 5% in the US and 6% in Europe, 
indicating the need to characterize the most notable risk factors.
One of the most common inherited CRCs is Lynch syndrome (LS), previously known as heredi-
tary non-polyposis colorectal cancer (HNPCC) syndrome, which accounts for 2 - 4% of all CRC 
cases (Lynch & de la Chapelle, 2003). The susceptibility is caused by germline mutations in the 
genes MLH1, MSH2, MSH6 and PMS2, which encode proteins responsible for DNA mismatch 
repair (MMR) (Peltomaki, 2005). LS related cancers (1) are inherited in an autosomal domi-
nant manner, (2) have an earlier average age of onset of colorectal cancer than in the general 
population (45 years in Lynch syndrome v. 65 years in the general population), (3) are mostly 
found in the proximal colon, with an increased risk of malignant disease at certain extra-colonic 
sites and (4) have accelerated carcinogenesis. LS cancers express high microsatellite instability 
(MSI) due to MMR malfunction (Aaltonen et al., 1993), which leads to an increased mutation 
rate. Moreover, MSI is found in 10 - 15% of sporadic CRCs. Hypermethylation of the promoter 
region and subsequent inactivation of MLH1 leads to MMR malfunction and causes the MSI 
phenotype in sporadic cancers (Hawkins & Ward, 2001). 
Diagnosis of Lynch syndrome specifically relies on familial genetic background and early age 
of cancer onset (Vasen et al., 1999). After diagnosing an LS family contiguous pre-symptomat-
ic surveillance and predictive gene counseling can be offered to its mutation carriers. Unfortu-
nately, a drawback of the international criteria is that small LS families or LS patients without 
family history of cancers are not easily diagnosed. Moreover, MSI analysis and/or expression 
studies of MMR proteins by immunohistochemical (IHC) staining may indicate an MMR de-
fect in a tumor but, without finding and assessing a pathogenic germline MMR gene mutation 
in a patient, are not enough to confirm LS (Weissman et al., 2012). Many missense mutations, 
which cause only a single amino acid substitution in a protein, do not always segregate with 
a cancer phenotype in a family and the interpretation of their pathogenicity is often difficult, 
complicating LS diagnoses and counseling. Currently variants are classified into five groups: 
pathogenic, probably pathogenic, no known pathogenicity, probably no pathogenicity and ef-
fect unknown (Kansikas, Kariola & Nystrom, 2011).
Effects of biochemical defects of non-truncating MSH2 mutations found in putative LS families 
were studied by analyzing protein stability, protein DNA binding and ATP mediated DNA re-
lease ability. Our previous findings showed that most studied mutations abolished MMR func-
tion in the in vitro MMR assay, but mechanisms for MMR malfunction remained unknown 
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(Ollila et al., 2006). Here, we observed that mutations affecting a certain biochemical property 
tended to cluster together in specific domains of the MSH2 protein, suggesting that pathogenic 
mutations may be clustered in specific protein regions essential for MMR activity. Additionally, 
specific functional assays showed usefulness in cases where the variant was clinically associ-
ated with cancer, was MMR proficient but in specific functional assays expressed malfunction. 
Studies on inherited cancers, e.g. LS, are important since they may clarify molecular mecha-
nisms associated with tumorigenesis in general. Nevertheless, cancers linked to a dominantly 
inherited predisposition are a minority in the whole CRC burden and the etiology in most can-
cers seem to be strongly associated with lifestyle factors and aging (Bingham, 1996, Lipkin et 
al., 1999, Bingham & Riboli, 2004, Fearon, 2011). Western style diet (WD), energy high, rich 
in fat and scarce in fiber, calcium, vitamin D and folate is one of the lifestyle factors shown to 
promote cancer in animals (Lipkin et al., 1999, Newmark et al., 2001). 
Here we studied dietary effects on proteome expression in normal colonic mucosa of Mlh1+/- 
mice analogous to LS mutation carriers, and their wild type littermates. Remarkably, the sta-
tistically significant expression changes caused by WD occurred predominantly in mutation 
carriers and indicated metabolic disturbances and increased toxicity in the cells. However, our 
studies suggest that genetic predisposition and diet effects do not necessarily interact since we 
did not find any effect of Western diet on Mlh1 expression in colonic mucosa. These two risk 
factors may rather drive cellular processes towards a common goal and cause changes, which 
will eventually push cellular homeostasis over the brink towards tumorigenesis.
13
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REVIEW OF THE LITERATURE
CANCER
Cancer is a group of more than 100 different diseases. Nevertheless they share common fea-
tures of deregulated cell growth and homeostasis. Transformation of the normal cells to cancer-
ous ones can be described as a multi-step acquirement of several alterations in cell physiology 
that lead to malignant growth. Alterations that enable normal cells to turn into cancerous cells 
are sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, activating invasion and metastasis, reprogram-
ming energy metabolism, evading immune destruction, tumor-promoting inflammation and ge-
nome instability and mutations. (Hanahan & Weinberg, 2011) 
Further support for Hanahan’s & Weinberg’s list of the ten hallmarks of cancer has come from 
work done by the Cancer Genome Atlas consortium and an enormous sequencing project, which 
included various cancers (Vogelstein et al., 2013). Cancer genomes harbor hundreds of muta-
tions in different genes and seem to be highly heterogeneous. However, even phenotypically 
different cancers were found to resemble each other when the mutated genes found in different 
cancers were organized according to the molecular pathways they are involved in. For example, 
one cancer can have a mutation in K-Ras, another cancer in Mek, and third in Erk. Although, 
genetic changes in them are then different they all have a deregulated Ras-Mek-Erk pathway. 
Each separate cancer has an average of 12 different deregulated pathways (DNA damage con-
trol, TGF-b, MAPK, STAT, PI3K, RAS, cell cycle and apoptosis, NOTCH, Hedgehog, APC, 
chromatin modification, and transcriptional regulation) that regulate three cellular processes - 
cell fate, cell survival and genome maintenance (Vogelstein et al., 2013). Information from can-
cer genome studies recognizes cancer as a pathway disease rather than a mere genetic disease. 
Oncogenes and tumor suppressor genes
Most mutated genes in cancer can be classified as (proto-) oncogenes or tumor suppressor 
genes (TSG). Proto-oncogenes regulate cell differentiation and cell cycle progression through 
cellular signal transduction and mitogen-regulated pathways. When constitutively activated, 
proto-oncogenes become oncogenes and turn normal cells into rapidly dividing (pre)-cancerous 
cells. Mechanisms of constitutive activation are mutations, over-expression and chromosomal 
translocations. Mutations in a gene can affect the active site of the protein leading to permanent 
activation of cell division. On the other hand, mutations in the promoter region can increase 
gene expression, which causes higher oncoprotein abundance. Gene duplications increase gene 
copy number and consequently protein expression is higher. Chromosomal translocations re-
locate proto-oncogenes to a new locus and may activate the expression of the proto-oncogene, 
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especially if translocated under the promoter of a constitutively expressed gene. Transloca-
tions may also result in fusion of proto-oncogenes and other genes forming a hybrid protein, 
which may exhibit highly oncogenic activity. Oncogenes can be classified as growth factors, 
kinases, regulatory GTPases and transcription factors. Growth factors induce cell proliferation 
(e.g. PDGF). Kinases can be split into three sub-groups, which are tyrosine kinases, found in 
the cellular membrane (e.g. EGFR, PDGFR, VEGFR), cytoplasmic tyrosine kinases, which 
mediate signals in cell proliferation, survival and migration (e.g. Src-family, BCR-ABL, BTK) 
and cytoplasmic serine/threonine kinases involved in cell cycle regulation, differentiation/pro-
liferation and apoptosis (e.g. Raf kinase and cyclin-dependent kinases). Regulatory GTPases 
maintain signal transduction in the cytoplasm and are involved in cellular differentiation (e.g. 
RAS, RHO, RAB). Transcription factors include a large group of proteins, which regulate cell 
proliferation (e.g. MYC). (Hanahan & Weinberg, 2011)
While proto-oncogenes promote cellular growth, TSGs keep cellular growth in control. The 
first tumor suppressor gene was discovered by studying families with inherited eye cancers, ret-
inoblastomas during the ‘70s. Individuals with the disease carry a germline mutation in one al-
lele of the retinoblastoma (Rb1) gene, which encodes a protein that suppresses cell proliferation 
and growth. Somatically gained mutation or deletion inactivates the other allele of Rb1 during 
childhood and starts tumorigenesis. The event of inactivation of the other allele was named loss 
of heterozygosity (LOH) and the mechanism according to its founder is called Knudson’s two 
hit hypothesis (Knudson, 1971, Berger, Knudson & Pandolfi, 2011). Tumor suppressors can be 
grouped according to their functions into repressors of cell cycle progression, so called gate-
keepers (e.g. RB1, CD2A1), pro-apoptotic proteins, which direct cells toward apoptosis if DNA 
damage is irreparable (e.g. BAX family), negative regulators of growth-promoting pathways 
(e.g. APC), and genes involved in DNA maintenance, so called caretakers. Caretakers are a 
large group of tumor suppressors consisting of more than 100 genes involved in different DNA 
repair mechanisms (e.g. MLH1, MSH2, MSH6, BRCA1/2, ATM). (Hanahan & Weinberg, 2011) 
Defects in DNA repair mechanisms directly lead to genome instability that enables oncogene 
activation.
Misdirected epigenetic modifications in cancer
Cancer develops as a result of complex deregulation of oncogenes and TSG. In addition to 
genetic factors that affect gene regulation, another layer of complexity has been added when a 
growing body of evidence showed that inherited epigenetic changes can affect regulation of on-
cogenes and TSGs. Epigenetic means of affecting gene expression in cancer have been mainly 
investigated in respect of DNA and chromatin methylation and different histone modifications. 
The classic model of CRC development by Vogelstein has been revised and abnormal DNA 
methylation implemented as an early event in neoplastic changes. (Allis, Jenuwein & Reinberg, 
15
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2007)
The most common way of epigenetic regulation of gene expression is by DNA methylation of 
cytosine (C) residues in CpG islands. CpG islands are DNA regions at least 500 base pairs in 
length containing more than 55% cytosine and guanine (G) consecutively following each other 
with an observed-to-expected CpG ratio greater than 65% (Takai & Jones, 2002). CpG islands 
are found in 70% of the human gene promoters (Saxonov, Berg & Brutlag, 2006). Hypermeth-
ylation of cytosines causes inactivation of the promoter and hypomethylation can cause activa-
tion. Aberrant DNA methylation is associated with CRC development. Most cancers exhibit ge-
nome wide DNA hypomethylation (Feinberg & Vogelstein, 1983, Feinberg et al., 1988, Makos 
et al., 1992), which relaxes the DNA structure and may cause over-expression of oncogenes and 
genome instability. Interestingly, promoters of tumor suppressors are often aberrantly hyper-
methylated in cancer leading to gene inactivation (Jones & Laird, 1999). The genes MLH1 and 
APC are commonly found to be inactivated in CRC by promoter hypermethylation (Thibodeau 
et al., 1998), especially in familial syndromes, where sometimes the second hit occurs through 
hypermethylation (Nakagawa et al., 2001, Suter et al., 2003). 
Aberrant DNA methylation is related to aging and implied to be an early event in CRC devel-
opment (Issa, 1999). DNA methylation is a reversible change, which makes it interesting as 
a target for drug treatment. In addition, diet, particularly dietary folate, and energy metabol-
ic pathways, which involve sirtuins, isocitrate dehydrogenases, synthesis of co-enzymes (e.g. 
2-oxoglutarate and FAD) seem to be profoundly involved in DNA methylation, histone modi-
fications (methylations and acetylations) and cancer development (Slattery et al., 1999, Wellen 
et al., 2009, Figueroa et al., 2010, Lu et al., 2012). 
Colorectal cancer (CRC)
The colon mucosa consists of crypts, which are approximately 50 cells deep. Replicating stem 
cells on the bottom of the crypt migrate upwards while differentiating into epithelial cells. Cells 
at the top of the crypt trigger apoptosis, die and shred into the colon lumen (Fig. 1). During their 
lifetime, the majority of people will develop some neoplastic changes in the colon epithelial 
tissue, but only a few of those will directly lead to CRC. (Kinzler & Vogelstein, 1996, Kwong & 
Dove, 2009) The most common neoplastic changes are hyperplastic and inflammatory polyps, 
which are not directly considered pre-cancerous, but may indicate higher risk of developing 
adenomatous polyps (adenomas). Adenomas may over time change into cancer and they are 
considered potentially malignant. 
If adenomatous cells accumulate multiple mutations in oncogenes or TSGs and invade the 
colon or rectum wall, they can access blood and lymph vessels. Once in the lymphatic sys-
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tem, cancerous cells may disseminate firstly 
into nearby lymph nodes and later into liver 
forming metastases. (Weinberg, 2007)
To date, two hypotheses of CRC morpho-
genesis exist, bottom-up and top-down. 
The most widely accepted hypothesis, bot-
tom-up, proposes that stem cells gain initial 
mutations, which lead to polyp formation at 
the top of the crypt. Polyps are exposed to 
the genotoxic surroundings of the colon con-
tent and can more easily accumulate further 
mutations and progress over time to CRC 
(Boman & Huang, 2008). This hypothesis is 
challenged by a top-down proposal that first 
mutations happen in the cells at the top of the 
crypt causing an adenomatous polyp, which 
advances toward the bottom of the crypt 
(Shih et al., 2001, Kwong & Dove, 2009). 
At the beginning of ‘90s two famous CRC 
researchers, Fearon and Vogelstein proposed 
a widely accepted genetic pathway for CRC 
tumorigenesis (Fearon & Vogelstein, 1990), 
which was later revised (Kinzler & Vogel-
stein, 1997). Their model postulates that five 
to seven molecular genetic alterations are 
needed in a normal epithelial cell for development of carcinoma. These alterations are most 
commonly found in tumor suppressors such as APC, p53 and K-Ras as well as genes on the 
chromosome 18q. In addition to genetic mutations, early epigenetic changes advance tumor 
progression through genome-wide loss of DNA methylation (hypomethylation) due to aging 
and focal gains of DNA methylation (hypermethylation). Hypomethylation of oncogene pro-
moters can lead to biallelic expression and hypermethylation of TSG, which can lead to inac-
tivation of genes with the ultimate goal of enabling cells to drive neoplastic processes (Fig. 2). 
(Allis, Jenuwein & Reinberg, 2007)
The TSG APC is mutated in ~80% of sporadic colon cancers (Powell et al., 1992). It forms 
a protein complex with b-catenin preventing the translocation of b-catenin into the nucleus 
(Smits et al., 1999). Normally, the cytoplasmic level of b-catenin is increased in the presence 
Fig. 1 Schematic structure of colon tissue shows 
organization of the epithelial cells (modified from 
Weinberg, 2007). Stem cells are at the bottom of the 
crypt: green, proliferative cells are found in the low-
er third of the crypt: red, and differentiated cells are 
in the remaining two thirds of the crypt: blue. Yellow 
cells are goblet cells. The cells at the top of the crypt 
undergo apoptosis and shred into the colon lumen.
17
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of Wnt signal, which leads to b-catenin translocation into the nucleus and activation of several 
transcription factors. APC mutations can cause malfunctioning in APC signaling and prevent 
formation of the APC-b-catenin complex. Excess unbound b-catenin may trigger activation of 
the oncogenes c-Myc and cyclin D1 (He et al., 1998, Tetsu & McCormick, 1999), which lead to 
uncontrolled cell cycle progression and proliferation if expressed constitutively.  
The p53 gene is a widely mutated tumor suppressor in several types of cancers. Most character-
ized mutations lead to loss of function or abnormal function of p53 (Cho & Vogelstein, 1992, 
Greenblatt et al., 1994). It mediates the cellular response to DNA damage and prevents passing 
of mutations to daughter cells (Lane, 1992). Mutated p53 has also been associated with the 
transition of adenoma to carcinoma in CRC (Cho & Vogelstein, 1992). 
Occurrence of LOH in the 18q chromosome has been commonly seen in CRC. LOH in this 
particular region increases in later developmental stages of CRC (it is found in 73% of carcino-
mas) (Cho & Vogelstein, 1992). In-depth analysis of the region that is lost in the 18q chromo-
some underlined tumor suppressors SMAD4 and SMAD2, which are indeed frequently mutated 
in CRC (Thiagalingam et al., 1996). SMAD4 and SMAD2 are involved in the transforming 
growth factor – beta (TGF-b) pathway and are responsible for cell proliferation, differentia-
tion, apoptosis and adhesion (Xu et al., 2000). Chromosomal deletion in 18q and mutations in 
Fig. 2 Different stages of colorectal cancer (CRC) development and progression (modified from Allis, 
Jenuwein & Reinberg, 2007). Abnormalities in APC and mismatch repair (MMR) genes are early chang-
es in normal epithelium leading to early adenoma. Increase of epigenetic abnormalities (increase of red 
in the bar) is postulated to be one of the first changes in CRC development. Complete inactivation of 
APC and/or MMR genes leads to intermediate adenoma, which later usually needs mutation in K-Ras 
or some of the genes at the 18q locus to develop into adenoma. Late adenoma develops into invasive 
carcinoma after obtaining mutation in p53.
18
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SMAD4 and SMAD2 can compromise the TGF-b pathway effect on proliferation.
The K-Ras gene is a frequently mutated oncogene in CRC (30 - 50%) and mutations in it 
seem to be required quite early in adenoma-carcinoma transition. K-Ras codes a small 21 kDa 
GTPase protein, which transmits growth signals when GTP is bound to it. K-RAS is inactivat-
ed once GTP is hydrolyzed (Bos et al., 1987). The majority of mutations affect the ability of 
K-RAS to hydrolyse GTP, which in turn causes a constitutive signal to cells for growth and 
proliferation (Vogelstein et al., 1988). 
RISK FACTORS IN CRC
Colorectal cancer and cancer in general, is considered a genetic disease. Moreover, scientific 
and epidemiological evidence support that diet, lifestyle and social practice substantially con-
tribute to the development of cancer and CRC in particular. Some evidence of diet and other 
lifestyle effects on CRC comes from studies on the Japanese population. Incidence of CRC 
used to be very low in Japan before major changes in lifestyle, especially the westernization of 
diet, after which the incidence increased to the level in Western countries (Nagata et al., 2001). 
Additional support to the effects of diet on CRC comes from studies on Japanese who migrated 
to the USA. These Japanese migrants developed similar risk to CRC as the native population 
(Haenszel, 1961, Buell & Dunn, 1965, Haenszel & Kurihara, 1968). Genetic factors and diet 
may have a pleiotropic effect on gastrointestinal tract, hormonal balance and epigenetic chang-
es (Little, Horowitz & Feinle-Bisset, 2007). Different risk factors in CRC will be discussed in 
more detail later in this chapter.
Inherited predisposition to CRC
The majority of CRCs (~75%) develop sporadically in individuals without inherited suscepti-
bility, while the rest are CRCs with a family history of CRCs. In about 10% of CRCs predispo-
sition is caused by determined germline mutation, and these CRCs are considered hereditary/
inherited. The major hereditary CRC syndromes are familial adenomatous polyposis (FAP), 
MYH-associated polyposis (MAP), Lynch syndrome (LS) and rare colon cancer syndromes. 
Although familial colon cancer syndromes are quite rare, they have greatly helped to under-
stand cellular, biochemical and genetic mechanisms of CRC. 
FAP is a rare autosomal dominant syndrome caused by germline mutations in the APC gene, 
which cause truncated APC with abnormal function (Bulow, 1987). Clinical characteristics of 
this disease are early age of onset and development of numerous polyps. Polyps can already oc-
cur in childhood and if left untreated some of these polyps will develop into malignant cancer. 
In addition to the inherited mutation a somatic mutation or LOH is needed for cancer develop-
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ment. More than 1191 different variants of the APC gene have been reported (http://www.in-
sight-group.org). Predominantly, variants are deletions and substitutions that lead to frameshifts 
and nonsense variants of the protein. The most common APC mutation found in 10% of FAP 
patients is a deletion of AAAAG in codon 1309 (Yan et al., 2002). The position of the germline 
mutation in APC determines whether the second hit is a truncating mutation or loss of the sec-
ond allele (Lamlum et al., 1999). 
In 1913 famous scientist Alderd S. Warthin described another highly penetrant syndrome as 
a hereditary occurrence of gastric cancer (Lynch & Krush, 1971). Later in the ‘70s Henry T. 
Lynch described the same syndrome but this time he followed colon and extracolonic cancers 
(uterine and stomach) of 600 descendants of an original family described by Warthin. The 
characteristic of this syndrome was lack of polyps and was thus originally named hereditary 
nonpolyposis colorectal cancer (HNPCC). Since many patients have polyps and tumors other 
than CRC, the syndrome was renamed as Lynch syndrome. LS is the most common inherited 
CRC accounting for 5 - 8% of all cases and 2 - 3% of all CRCs (Lynch & de la Chapelle, 1999, 
Lynch & de la Chapelle, 2003). In the early ‘90s germline mutations in MSH2, MLH1, MSH6 
and PMS2 were found to segregate with cancers in LS families (Leach et al., 1993, Lindblom et 
al., 1993, Peltomaki et al., 1993, Papadopoulos et al., 1994, Nystrom-Lahti et al., 1995).  
Lynch syndrome (LS)
Once the connection between mutated MMR genes and LS was established the finding that 
MMR deficiency in Saccharomyces cerevisiae caused microsatellite instability (MSI) quick-
ly led to the correct prediction that LS tumors also show MSI (Aaltonen et al., 1993, Jiricny, 
1994). Ever since, MSI has been a strong hallmark of LS cancers together with an early age of 
onset (~45 years) and the proximal colon being the predominant site of occurrence (Lynch & de 
la Chapelle, 1999, Peltomaki, Gao & Mecklin, 2001). One of the common characteristics of LS 
are various extra-colonic tumors, mainly found in the endometrium, ovaries, stomach and skin. 
Endometrial cancer has an even higher penetrance (50 - 60%) than CRC in females (Vasen et 
al., 1996, Aarnio et al., 1999). 
Since the discovery of the first germline mutations in MLH1 and MSH2, 2812 unique variants 
have been reported in five different MMR genes. MLH1 is the most frequently mutated gene 
with 40% of variants (1117) followed by MSH2 33% (919), MSH6 17% (490), PMS2 7.5% 
(214) and MLH3 2.5% (72) (www.insight-group.org). The predominant changes in MMR genes 
are missense mutations and insertions/deletions. 
Despite the large number of reported mutations, founder mutations, which originate from the 
same ancestry and thus affect several families in a specific area, are rare. The ones which have 
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been reported are a splice site mutation in MLH1 exon 6 (MLH1 c.454-1G>A) and a deletion of 
MLH1 exon 16 (MLH1 c.1732-2243_1896+404del) in Finland (Nystrom-Lahti et al., 1995), a 
deletion of exons 1- 6 in MSH2 (MSH2 Paracentric inversion) in the US (Wagner et al., 2002), 
and a splice-site mutation in intron 5 of MSH2 (c.942+3A>T) in the US and England (Froggatt 
et al., 1999). Furthermore, about 30% of LS patients in Ashkenazy Jews carry a missense mu-
tation in MSH2 (MSH2 c.1906G>C) (Guillem et al., 2003, Guillem et al., 2004).
The MMR genes are tumor suppressors and according to Knudson’s two-hit hypothesis both 
of their alleles need to be inactivated in order to develop cancer. In LS patients one allele is 
inactivated by a germline mutation and the second allele can be inactivated by LOH or gene 
conversion but also by promoter hypermethylation (Yuen et al., 2002, Zhang et al., 2006). The 
second hit leads to deficient MMR activity in the cell. If DNA polymerase proofreading fails 
in repair there is no functional MMR mechanism, and thus DNA, especially repetitive regions 
(microsatellite sequences), become prone to mismatches. Changes such as insertions/deletions 
may also cause alterations in the reading frame of genes that contain microsatellite sequences in 
their coding sequence. Indeed, most affected genes in CRC are suppressors of cellular growth 
e.g. TGFbRII, IGFIIR, pro-apoptotic regulators e.g. BAX as well as MMR genes MSH6 and 
MSH3, which contain mononucleotide repeats in their coding regions. (Markowitz et al., 1995, 
Malkhosyan et al., 1996, Souza et al., 1996, Rampino et al., 1997, Duval & Hamelin, 2002)
Clinicians have tried to create international criteria with an aim of unifying LS diagnostics and 
distinguishing LS patients from sporadic CRC. At the moment, active criteria consist of diag-
nostic guidelines termed Amsterdam criteria II after Amsterdam criteria I was revised in 1999 
(Vasen et al., 1999). Amsterdam criteria are very specific but unfortunately lack sensitivity and 
many LS families are not diagnosed (e.g. families with just some cancers or families without 
Table 1. Amsterdam criteria II and Bethesda guidelines are existing criteria for LS dignostics 
(Vasen et al., 1999; Umar et al., 2004)
AMSTERDAM CRITERIA II* BETHESDA GUIDELINES**
At least three relatives should have                    
histologically verified LS cancers. One of them 
should be a first-degree relative of the other two. 
CRC diganosed in 2 or more first- or second       
degree relatives with a LS cancer, one of the       
tumors diagnosed before age of 50
One of the relatives should be below 50 years of 
age when the CRC is diagnosed. 
Presence of LS associated cancers, regardless of 
age.
At least two successive generations should be 
affected. 
CRC diganosed in 2 or more first- or second      
degree relatives with a LS cancer
Familial adenomatous polyposis (FAP) should be 
excluded. CRC diagnosed before age of 50
Tumors should be verified by pathological exam-
ination. 
CRC with the MSI-high histology diagnosed before 
age of 60
* all conditions have to be fulfilled
** any of the conditions have to be fulfilled 
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enough information) (Rodriguez-Bigas et al., 1997). Consequently, the Bethesda guidelines 
were established by implementation of an LS hallmark MSI (Umar et al., 2004). Detailed diag-
nostic criteria for LS can be found in Table 1.
Although MSI is not only a specific feature of LS tumors but is also detected in ~15% of spo-
radic CRCs due to focal hypermethylation of the promoter of MLH1 (Hawkins & Ward, 2001, 
Lawes, SenGupta & Boulos, 2003), it is widely used as a screening method for MMR defect 
in tumors. Generally, MSI studies employ a panel of five microsatellite markers and if two of 
them show instability the tumor is considered MSI-high (Boland et al., 1998). Another widely 
used diagnostic method is to study the expression of MMR proteins in a tumor by immuno-
histochemistry (IHC). The tumor showing high MSI and no staining for one or several MMR 
proteins is MMR deficient. Although ~34% of mutations found in MMR genes are truncating, 
a significant amount of mutations are non-truncating (~32%) and difficult to distinguish from 
polymorphisms (InSiGht, 2014). The genes with non-truncating variants of uncertain signifi-
cance (VUS) (Goldgar et al., 2008) can still be expressed in tumors, but the expressed proteins 
are not necessarily functional (Mangold et al., 2005, Raevaara et al., 2005). Functional assays 
are used to assess VUS pathogenicity and thus help clinical management of families in genetic 
testing, counseling, and pre-symptomatic surveillance of its VUS carriers with a final aim of 
successful reduction in mortality (InSiGht, 2014). It is notable that failing to diagnose LS can 
mislead medical treatment of a CRC patient. For example standard chemotherapeutic drug 
treatments for cancer such as methylating agents give rise to mispairs (O6-methylguanine (MeG) 
– C and MeG – T) in DNA enriching mutations and induce cell death (Karran, 2001). However, 
MMR deficient cells are more resistant to death when they are treated with these agents. On the 
other hand, MMR deficient cells are more sensitive to death than MMR proficient cells when 
they were treated with interstrand crosslinking agents such as 1- (2-chloroethyl)-3-cyclohex-
yl-nitrosourea (Fiumicino et al., 2000).
Mismatch repair mechanism
Mismatch repair maintains DNA integrity by detecting and repairing mismatches. A proficient 
MMR system distinguishes the newly synthesized DNA strand, recognizes base/base impairs 
or small insertion/deletion loops (IDLs), which arise during the replication and repairs damage 
preventing formation of mutations. First knowledge of the MMR mechanism came from the 
studies in E. coli, in which the MutS homodimer recognizes post-replicative errors and recruits 
the MutL homodimer forming a ternary complex. The complex activates, in an ATP-dependent 
manner, the latent endonuclease activity of MutH, a member of the type II family of restriction 
endonucleases. Activation leads to incision of a repairable DNA strand at a hemi-methylated 
GATC site, which is the recognition sign for the newly synthesized DNA strand in prokaryotes 
(Wagner & Meselson, 1976, Glickman, van den Elsen & Radman, 1978). The strand with the 
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impaired base is digested. DNA polymerase III corrects the mismatch and DNA ligase seals the 
nick. The core proteins MutS and MutL are highly conserved from prokaryotes to eukaryotes 
showing their importance for homeostasis of the cells. Five different MutS homologues (MSHs) 
have been identified in human cells, but only three of them MSH2, MSH3 and MSH6 are in-
volved in MMR. Furthermore, human cells contain four MutL homologues (MLH) MLH1, 
MLH3, PMS1 (post-meiotic segregation 1) and PMS2, whereas PMS1 does not have a known 
role in MMR. So far, no homologue of MutH has been found in other organisms. 
Contrary to prokaryotic MMR proteins, which function as homodimers, in eukaryotes they 
function as heterodimers. The MutS homologue proteins MSH2 and MSH6 compose the most 
important MMR complex MutSa, which recognizes, binds to and initiates the repair of base-
base mismatches and small IDLs (Drummond et al., 1995, Palombo et al., 1995), while MutSb 
composed of MSH2 and MSH3 repairs mainly larger IDLs (Acharya et al., 1996, Palombo et 
al., 1996). In yeast, MutSb repairs some base-base mismatches (Harrington & Kolodner, 2007) 
and recently in in vitro studies of MMR this complex exceeds MutSa in repair of dinucleotide 
loops (Kantelinen et al., 2010). However, in addition to the incorrectly paired bases during 
DNA replication e.g. G/T (Hunter et al., 1987), the MMR system repairs chemically-induced 
DNA lesions such as alkylation-induced O6-methylguanine paired with cytosine or thymine 
(Duckett et al., 1996), 1,2-intrastrand (GpG) cross-links generated by cisplatin (Mello et al., 
1996), UV-induced photoproducts (Wang et al., 1999) and 8-oxoguanine (Colussi et al., 2002).
MutLa is composed of MLH1 and PMS2, MutLb	 of MLH1 and PMS1 and MutLg of MLH1 
and MLH3 (Li & Modrich, 1995, Flores-Rozas & Kolodner, 1998). MutSa recruits MutLa and 
together they direct MMR and interact with other proteins. MutLa recruits downstream repair 
proteins and has an endonuclease activity substituting the MutH role in eukaryotic MMR (Yang, 
2007). MutLg seems to participate, although inefficiently, in the repair of base-base mismatches 
and single-nucleotide IDLs (Cannavo et al., 2005, Korhonen, Vuorenmaa & Nystrom, 2008). 
Other factors needed for human MMR are the homo-trimeric proliferating cell nuclear antigen 
(PCNA) involved in DNA replication, the single-stranded binding-factor replication factor A 
(RPA) (Lin et al., 1998) and the non-histone chromatin component high-mobility group box1 
(HMGB1) (Yuan et al., 2004). MSH6 and MSH3 interact with PCNA through PCNA-interact-
ing motifs near N termini (Umar et al., 1996, Kleczkowska et al., 2001) and replication factor C 
(RFC) directs degradation reaction (Dzantiev et al., 2004). Exonuclease 1 (EXO1) excises the 
mismatch in both directions (3’à5’ and 5’à3’) (Genschel, Bazemore & Modrich, 2002) inter-
acting and forming tight heterodimeric complexes between MSH2 and MLH1 (Schmutte et al., 
2001, Sun, Zheng & Shen, 2002). DNA polymerase d (Pol d) repairs DNA (Longley, Pierce & 
Modrich, 1997) and DNA ligase seals the nick (Fig. 3). 
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Structure and function of MutSa
MutSa, a heterodimer of MSH2 and MSH6 forms an oval disc pierced by two channels like 
the letter θ. Both proteins of the complex contain five functional domains (Fig. 4). Domain 
1 is a mismatch-binding domain with a highly conserved Phe-X-Glu pattern located at the N 
terminus of MSH6 that contacts the mismatch (Malkov et al., 1997, Dufner et al., 2000). The 
connector domain (domain 2) is involved in allosteric signaling and bridges the lever domain 
(domain 3) and the ATP binding cassette (ABC)-ATP domain (domain 5). Domain 3 spans the 
entire distance between domains 4 and 5, and domain 4 makes significant non-specific DNA 
interactions (Warren et al., 2007). 
Fig. 3 Mismatch repair. MutSα (consisting of MSH2 (dark blue) and MSH6 (green) or MutSβ (consisting 
of MSH2 and MSH3), depending on the type, recognizes mismatch. MutSα binds to MutLα (consisting 
of MLH1 (violet) and PMS2 (magenta) and forms a ternary complex, which slides along the DNA in an 
ATP-dependent manner. EXO1 excises the mismatch, Polδ  synthesizes DNA and DNA ligase ligates 
the nick. This process is helped by replication factor C (RFC (light brown and white pentagon), prolifer-
ative cell nuclear antigen (PCNA (brown ring) and replication protein A (RPA (light blue circles). Figure 
is modified from Jiricny, 2006.
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The ATP domain is the most highly con-
served region among MutS homologues e.g. 
domains of E.coli MutS and human MSH2 
are 48% identical (Warren et al., 2007). 
MSH proteins contain ATP binding motifs, 
Walker A and Walker B, which are highly 
conserved among prokaryotes and eukary-
otes (Walker et al., 1982). MutSα contains 
two non-equivalent ATP hydrolytic cen-
ters located at the C terminus of MSH2 and 
MSH6 (Martik, Baitinger & Modrich, 2004). 
Research in Saccharomyces cerevisiae has 
been shown that the ATPase activity of both 
Msh6 and Msh2 have an affect on each other 
(Antony et al., 2006). In the presence of ATP 
and Mg2+ MutSa rapidly dissociates from 
complexes with either homoduplex or het-
eroduplex DNA. In the case of heteroduplex 
DNA, with ends blocked with streptavidin 
or the lac repressor, MutSa remains trapped 
on the DNA, suggesting that the complex ac-
tually slides along the DNA (Gradia, Acha-
rya & Fishel, 1997, Blackwell et al., 1998, 
Iaccarino et al., 2000). 
MutS complexes recognize mismatches, 
IDLs or chemically modified bases in the 
presence of a strand break, which is ~125-
150 nucleotides away (Genschel, Bazemore & Modrich, 2002) and recruits MutLa. The newly 
formed complex releases the mismatch in order for the mismatch to be repaired and slides 
along the DNA. Two models exist of the translocating and sliding MutSa, molecular switch and 
active translocation models. In the first model, ATPase activity and adenine nucleotide-bind-
ing domains of MutSa regulate mismatch binding as a molecular switch (Gradia, Acharya & 
Fishel, 1997, Gradia et al., 1999). MutSa is bound to the mismatch when ADP is in the adenine 
nucleotide-binding domain. When ADP exchanges for ATP MutSa dissociates from the mis-
match. The alternative model, active translocation, suggests that MutSa, possibly with MutLa 
after it is released from mismatch, translocates along the DNA hydrolyzing ATP (Blackwell 
et al., 1998, Martik, Baitinger & Modrich, 2004). This model is based on the fact that each 
Fig. 4 3D structure of MutSα while bound to the 
DNA. MutSα protein complex is a heterodimer com-
posed of MSH2 (different colors for different do-
mains) and MSH6 (white-gray). MSH2 consists of 
five domains (domain 1: magenta, domain 2: blue, 
domain 3: yellow, domain 4: dark grey and domain 
5: brown) and a structural motif helix-turn-helix (dark 
grey behind MSH6). Domain 1 is a DNA binding do-
main, domain 2 is a connector domain, which keeps 
MSH2 together and is responsible for allosteric 
regulation, domain 3 is called the lever domain and 
spans between domains 4 and 5. Domain 4 stabiliz-
es DNA connection with non-specific binding sites, 
and domain 5 is an ATPase domain. Cn3D software 
(NCBI) was used for 3D visualization of the protein 
from NCBI:Structure.
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subunit has two sites, which are called a latch site (L) and a D site. The L site on one subunit 
acts as a molecular latch, which physically blocks movement of DNA, but the D site allows 
DNA diffusion. Open or closed status of the L site is determined by ATP or ADP occupancy of 
the subunit nucleotide-binding domain. DNA diffuses through the D site for a period of time 
required for ATP turnover. That results in higher usage of ATP hydrolysis for DNA sliding than 
in the molecular switch model, which requires one ADP/ATP exchange for the conformational 
change of the protein complex.
Functional analysis of non-truncating MMR variants
A significant amount of reported alterations in MMR genes are non-truncating variants of un-
certain significance (http://www.insight-group.org) (Goldgar et al., 2008). Clinical diagnosis of 
Lynch syndrome consists of MMR protein expression analyses by immunochemical staining 
and MSI assessment. If results suggest LS, the next step is to screen for a mutation in MMR 
genes. When a pathogenic mutation is found, LS is confirmed, whereas in the case that no 
mutations are found, LS is less likely. When the found alteration is a VUS, the three steps de-
cision tree is proposed for its assessment (Couch et al., 2008). Here, after determining a VUS, 
the second step includes in silico analysis and an in vitro MMR assay. The variant indicating 
MMR deficiency with both assays suggests LS, whereas the variant showing MMR proficiency 
should be analyzed with other more specific biochemical assays (e.g. bandshift, protein stabili-
ty, sub-localization, and protein interaction assays) (Couch et al., 2008).
Functional assays determine either activity of MMR proteins in mismatch repair reactions (e.g. 
MMR assay) (Lahue, Au & Modrich, 1989, Nystrom-Lahti et al., 2002), or a more specific 
function of an MMR protein (e.g. binding to each other or binding and releasing DNA). Since 
the in vitro MMR assay does not provide the biochemical reason for MMR deficiency, more 
specific biochemical assays in step three are needed for that knowledge. Previous studies have 
clearly shown that MMR proteins can be functional in the in vitro MMR assay, but in vivo, 
proteins are not localized in the nucleus or their expression/stability is reduced (Raevaara et al., 
2005, Gammie et al., 2007).
Western diet as a CRC risk factor
Basic science has focused on studying genetic and molecular mechanisms causing cancer, but 
epidemiological studies have recognized dietary habits of Western populations as one of the 
high risk factors in etiology of CRC. Increased incidence of CRC correlates with the consump-
tion of a typical Western-style diet (WD) that contains high total energy, saturated fats of animal 
origin and low levels of fiber (Doll & Peto, 1981). Diet scarce in vitamin D, calcium and folate 
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was additionally associated with CRC risk (Lipkin et al., 1999). In 2007 The World Cancer 
Research Fund and The American Institute for Cancer Research acknowledged Western-style 
diet as a risk factor in CRC development estimating that 50 - 80% of CRCs can be associated 
with diet (http://www.dietandcancerreport.org). Epidemiological studies on the effect of diet 
on CRC in humans have, however, given ambiguous or even conflicting results and the mecha-
nisms through which diet affects CRC development still needs to be studied.
One of the main characteristics of Western diet is a high intake of meat. Studies on meat intake 
and CRC incidence often show either a positive correlation or no significant effect. Most case 
studies give a strong link between meat intake and CRC, while cohort studies show no sig-
nificant effect. (Norat & Riboli, 2001) Nevertheless meta-analyses utilizing different studies 
indicate a positive association between red meat and processed meat and CRC (Norat & Riboli, 
2001, Sandhu, White & McPherson, 2001). European Prospective Investigation into Cancer 
showed no significant association between red meat and CRC (Linseisen et al., 2002) proving 
inconsistency in epidemiological studies and difficulty in interpretation of their results. 
Already in the ‘50s high intake of dietary fiber was associated with reduced risk of CRC (Hig-
ginson & Oettle, 1960, Burkitt, 1969). Further studies agreed on the beneficial effect of fiber, 
claiming that fiber can contribute up to a 40% decrease in the risk of CRC. Furthermore, the 
positive effect of fiber can be altered depending on the source of fiber (fiber from grains, ce-
reals and fruit has the strongest effect) (Trock, Lanza & Greenwald, 1990, Fuchs et al., 1999, 
Bingham et al., 2003, Peters et al., 2003). Studies on the effect of fiber on colonocytes implies 
involvement of fiber fermentation by gut microbiota and their production of short-chain fatty 
acids in particular butyrate, which is the principal energy substrate of the colonocyte (Roediger, 
1990). In vitro studies also revealed that when cultured cells were treated with butyrate, growth 
arrest was induced. Also, caspase induced apoptosis of colon epithelial cells via altered signal-
ing of Fas-ligand death receptor was noted (Heerdt, Houston & Augenlicht, 1997, Chai et al., 
2000, Chapkin, Fan & Lupton, 2000). Additionally, butyrate inhibits histone deacetylases and 
promotes pro-apoptotic effects in colonocytes in vivo (Boffa et al., 1992, Richon et al., 2000, 
Wilson et al., 2010). 
Similarly to fiber, calcium and vitamin D are considered to reduce the risk of CRC. Evidence for 
the effect of calcium came from several studies (Marcus & Newcomb, 1998, Mobarhan, 1999, 
Pietinen et al., 1999) and D vitamin was later implemented based on studies, which showed that 
CRC incidence is higher in high geographical areas with less sunlight. Nevertheless, despite 
their high geographical area, the population of the Faroe Islands has lower CRC incidence, 
which is believed to be due to a fish- and dairy-rich diet (Dalberg et al., 1999, Tangpricha et 
al., 2001). A randomized trial with vitamin D and calcium supplements proved that these two 
compounds act together rather than separately (Grau et al., 2003). Lower calcium and vitamin 
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D levels are also proposed to inhibit apoptosis and favor cell proliferation (Peters et al., 2001), 
but the effects on early tumorigenesis remain to be elucidated. Studies on colorectal cell lines 
showed that extracellular calcium interacts with the parathyroid calcium-sensing receptor and 
promotes suppression of b-catenin/TCF signaling and activates E-cadherin expression, imply-
ing that lower calcium may affect these processes favoring CRC development (Chakrabarty et 
al., 2003).
Folate is essential for DNA synthesis, repair, methylation and it acts as a cofactor in biologi-
cal reactions (Weinstein et al., 2003). Humans cannot synthesize folate and therefore, its only 
source is from diet. Folate becomes biologically active when converted to tetrahydrofolate 
(THF) in the liver. Several cohort and case studies reported that low folate intake increases the 
risk of CRC (Benito et al., 1993, Giovannucci et al., 1995, Tseng et al., 1996, Giovannucci et 
al., 1998). Controversially, recent meta-analysis of trials on folic acid supplementation showed 
that supplementation with folic acid does not affect occurrence of cancer (Clarke et al., 2010, 
Vollset et al., 2013). Low folate intake affects DNA maintenance and DNA or histone methyl-
ation. The folate intermediate THF accepts one carbon unit from serine or glycine and forms 
5-methyl-THF (5-Me-THF) in a series of reactions. 5-Me-THF is an essential donor of methyl 
groups in the synthesis of methionine. S-adenosylmethionine (SAM) is synthesized from me-
thionine, and is used by all methylation reactions in the cell as a methyl donor producing S-ad-
enosylhomocysteine (SAH), which is further converted to homocysteine. 5-methyl-tetrahydro-
folate donates a methyl group to homocysteine in a reaction catalyzed by methionine synthase. 
Despite the known biochemical reactions of the folate pathway, exact mechanisms, which may 
lead to CRC development, remain unknown. 
METABOLIC STRESS AND CANCER
In 1927, Otto Warburg already discovered that cancer cells alter their glucose metabolism to 
produce most of their energy by glycolysis in the presence of oxygen, known as aerobic glycol-
ysis (Warburg, Wind & Negelein, 1927, Warburg, 1956a, Warburg, 1956b). This has become 
the center of attention in the past two decades and has led to new insights into the nature of 
cancer. 
Cancer cells energetically rely on aerobic glycolysis, which produces 2 molecules of ATP and 
pyruvate. The majority of pyruvate is further converted to lactate. In the presence of oxygen 
normal cells process glucose to pyruvate by glycolysis and pyruvate is further transported to 
mitochondria and processed in the tricarboxylic acid cycle (TCA) to carbon dioxide, resulting 
in higher energy production (Fain, Shestovskaia & Mamonova, 1975). Even though cancer cells 
seem to be inefficient in energy production, they adjust their metabolism to give them enough 
energy by up-regulating glucose transporters (e.g. GLUT1), which substantially increases glu-
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cose import into the cytoplasm. Up-regulation of glucose transporters is associated with activat-
ed oncogenes (e.g., RAS, MYC) and mutations in tumor suppressors (e.g., TP53) (DeBerardinis 
et al., 2008, Jones & Thompson, 2009). 
Additionally, increased glycolysis creates molecular intermediates for biosynthetic pathways 
such as biosynthesis of nucleosides and amino and fatty acids, which in turn enable cancer 
cell proliferation (Potter, 1958, Vander Heiden, Cantley & Thompson, 2009). Recent studies 
revealed that cancer reliance on glycolysis depends on the hypoxia response system, which 
independently from RAS can signal up-regulation of glycolysis (Kroemer & Pouyssegur, 2008, 
Semenza, 2010). Furthermore, the hypoxia response system can be activated by reactive oxy-
gen species (ROS) (Bonello et al., 2007), the levels of which are altered in many diseases (e.g. 
diabetes, obesity, cancer) and may contribute to disease pathogenesis (Halliwell, 2007, Nathan, 
2008, Trachootham, Alexandre & Huang, 2009).
Normal cells produce ROS at a low level in the electron transport chain, which is used in the 
regulation of cell signaling, proliferation and differentiation. Increase in ROS levels due to 
altered cellular metabolism can potentially damage cellular components and ultimately lead to 
cell death (Veal, Day & Morgan, 2007, Trachootham, Alexandre & Huang, 2009, Hamanaka & 
Chandel, 2010). 
Cellular levels of ROS in normal cells can 
be altered by nutrient excess/diet and lead to 
a pathological cellular state. Briefly, normal 
cells process eventually all nutrients by TCA, 
and released electrons are captured by nico-
tinamide adenine dinucleotide (NAD+) and 
flavin adenine dinucleotide (FAD). These 
electrons are later used in oxidative phos-
phorylation reactions to generate energy and 
the final acceptor of electrons is oxygen in 
the reaction that creates a molecule of water. 
(Wellen & Thompson, 2010) Increased con-
centration of electrons caused by nutrient 
excess/diet results in superoxide production, 
which is one of the ROS molecules (Turrens, 
2003). Superoxide is converted by superox-
ide dismutase into hydrogen peroxide, which 
is used for cellular signaling (Meng, Fukada 
& Tonks, 2002). Hydrogen peroxide can be 
Fig. 5 Activation and regulation of metabolic path-
ways in cancer. Cancer cells utilize aerobic gly-
colysis in the presence of oxygen for production 
of nucleosides, fatty acids and other molecular 
precursors needed for cellular proliferation. Aero-
bic glycolysis is favored in cancer cells. RAS and 
MYC favor aerobic glycolysis by up-regulating the 
Slc2a1 gene, resulting in production of the protein 
glucose transporter (GLUT1). IGF-1 stimulates the 
PI3K-Akt pathway, which in turn activates glycoly-
sis. Additionally high levels of ROS stabilize HIF1α, 
which translocates into the nucleus and activates 
glycolysis independently from RAS and MYC. TCA 
– tricarboxylic acid cycle, FAO – fatty acid oxidation, 
OXPHOS – oxidative phosphorylation. 
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converted into the highly reactive hydroxyl radical, which can damage DNA, membrane lipids, 
and proteins. In summary increased ROS may promote increasing DNA mutation rate, regulate 
signaling, transcription and promote inflammation contributing to cancer development (Fig. 5) 
(Wu, 2006, Lou et al., 2008). 
Adaptation to oxidative stress caused by ROS can in part be regulated by the unfolded protein 
response (UPR) (Cullinan & Diehl, 2006). UPR as a reaction to endoplasmic reticulum stress 
is altered in cancer and may have a role in cancer promotion (Moenner et al., 2007, Lou et al., 
2008, Healy et al., 2009). 
MOUSE MODELS IN CRC STUDIES
Many different mouse models have been created for studying changes in gene expression and 
pathways involved in carcinogenesis in colon and other intestinal tissues. The most studied 
model is the ApcMin strain that carries a truncating mutation at codon 850 (Moser, Pitot & Dove, 
1990). The heterozygote mouse develops on average 30 polyps in the small intestine. Addition-
ally, different mutations have been introduced in the Apc gene and various strains created e.g. 
ApcΔ716 (Oshima et al., 1995) and Apc1638N (Fodde et al., 1994). Both develop polyps in the small 
intestine: ApcΔ716 300 polyps on average, while Apc1638N only 3. Very few polyps are formed in 
the colon. Apc mutant mice have a short life span, on average 4-5 months because of heavy 
tumor load in the small intestine. (Taketo & Edelmann, 2009) 
MMR deficient mouse models
Due to the importance of MMR function in Lynch syndrome several mouse strains with a de-
fective MMR gene have been created to systematically study their role in initiation and devel-
opment of LS (Table 2).
Three different knock-out alleles of the MSH2 gene have been created (de Wind et al., 1995, 
Reitmair et al., 1995, Smits et al., 2000). The Msh2-/- mice develop normally and both sexes 
are fertile. The majority of the mice develop invasive T-cell lymphomas already within the first 
two months, and 50% of the homozygote Msh2-/- mice die during the first six months (Lowsky 
et al., 1997). Mice that survive longer than six months develop adenomas and adenocarcinomas 
in their small intestine and gland tumors (Schwartz & Torre, 1995). Heterozygous Msh2+/- mice 
are not distinguishable from wild type littermates; some develop tumors similar to Msh2-/- in 
their second year of life (Reitmair et al., 1996, de Wind et al., 1998). 
Msh3-/- mice have a mild cancer phenotype and they develop gastrointestinal tumors when the 
animals are older than 14 months; otherwise this mouse line is similar to the wild type mouse 
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(Edelmann et al., 2000).
Msh6-/- mice have similar cancers as Msh2-/- mice but the age of onset is slightly delayed and 
50% of the mice die at the age of 8-10 months. The earliest tumors are B- and T-cell lympho-
mas, and at the later stage of life some mice develop gastrointestinal tumors (Edelmann et al., 
1997, de Wind et al., 1999).
Double mutant mice Msh3-/-/Msh6-/- show no differences to Msh2-/- mice (de Wind et al., 1999, 
Edelmann et al., 2000), supporting the idea that MSH3 and MSH6 are alternative binding part-
ners of MSH2 in MMR.
Three different knock-out alleles for MLH1 have been published, and the mice express a similar 
phenotype to Msh2-/- mice, except that Mlh1-/- mice are infertile (Baker et al., 1996, Edelmann 
et al., 1996, Kawate et al., 1998). Mlh1-/- mice develop lymphomas and 50% of the mice die at 
the age of six months. Mice that survive the first six months develop gastrointestinal and skin 
tumors and live no longer than twelve months. Heterozygous Mlh1+/- mice are not distinguish-
able from wild type mice (Prolla et al., 1998, Edelmann et al., 1999).  
Pms2-/- mice express a less severe cancer phenotype than Mlh1-/- mice. Males are sterile but 
females are fertile, implying different roles of PMS2 and MLH1 in meiosis. Homozygous mice 
develop lymphomas and sarcomas already within the first six months, but 50% survival is until 
9 – 10 months and older mice never develop gastrointestinal or skin tumors (Prolla et al., 1998).
Table 2. Deficient MMR mouse lines1 with their phenotypes (adopted from Wei K et al., 
2002) 
Genotype 50% survival [months]
Tumor Fertility3 References
Incidence Type male / female
Msh2-/- 6 High Lymphoma, Gi, Skin +/+
Reitmair et al., 1995, de 
Wind et al., 1995, de Wind et 
al., 1998, Smits et al., 2000
Msh3-/- 18 Low2 GI tumors +/+ de Wind et al., 1999, Edel-mann et al., 2000
Msh6-/- 11 High Lymphoma, GI +/+
Edelmann et al., 1997, de 
Wind et al., 1999, Edelmann 
et al., 2000
Msh3-/- 
Msh6-/- 6 High Lymphoma, GI, skin +/+
de Wind et al., 1999, Edel-
mann et al., 2000
Mlh1-/- 6 High Lymphoma, GI, skin -/-
Baker et al., 1996, Edelmann 
et al., 1996, Kawate et al., 
1998, Prolla et al., 1998,
Pms1-/- >18 None None +/+ Prolla et al., 1998,
Pms2-/- 10 High Lymphoma & sarcoma -/+ Prolla et al., 1998,
1 mouse lines were created on C57BL/6J and various 129 substrains genetic backgrounds
2 Incidence of tumors was not significantly different from wild type
3 ‘+’ - fertile, ‘-’ - infertile
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Overall, inactivation of Msh2 or Mlh1 causes stronger cancer phenotypes than inactivation of 
Msh6 or Pms2. However, contrary to Lynch syndrome mutation carriers, heterozygous mice are 
not generally distinguishable from wild type littermates and do not express early-onset tumors. 
This is probably because of a shorter lifespan and smaller body size. (Wei, Kucherlapati & 
Edelmann, 2002, Taketo & Edelmann, 2009)
Mouse as a model for diet effects in the intestine
Most correlations between the consumption of different nutrients and colon cancer in human 
come from epidemiological studies. However, studies of diet effects on colon epithelia over a 
longer period of life are quite infeasible in humans due to a long life span, a high variability in 
individual dietary habits and heterogeneous genetic backgrounds. 
Isogenic mouse strains prove to be a useful tool in diet studies. Indeed, a Westernized diet, with 
high fat content, low on fiber, folate, vitamin D and calcium, has been shown to induce benign 
and malignant colon neoplasms in wild type mice without inherited cancer predisposition or 
carcinogenic treatments (Newmark et al., 2001, Newmark et al., 2009), suggesting that with 
increasing age WD itself is a considerable risk factor for CRC. Western diet has also been 
shown to increase the amount of intestinal neoplasms in the Apc1638N mouse, which is the most 
commonly used rodent model for human intestinal cancer (Yang et al., 1998). Many studies 
of different dietary components and complex diets have been performed with ApcMin mice but 
before our studies none with MMR deficient mouse lines (Tammariello & Milner, 2010). 
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AIMS OF THE PRESENT STUDY 
Both genetic and lifestyle factors have been shown to effect gene regulation and predisposition 
to cancer. The main aims in the present study were to analyze the biochemical effects of inher-
ited MMR gene variants derived from patients with putative Lynch syndrome and effects of 
Western style diet on colon cancer risk. 
More specific aims were: 
1. To examine the biochemical defects caused by inherited non-truncating mutations in the 
MMR gene MSH2. Gene variants were expressed in Sf9 cells. MSH2 protein variants were 
purified from total protien extracts and biochemically characterized. (I, II) 
Furthermore, to study the effects of Western-style diet we conducted an animal diet study. CRC 
predisposed mouse (Mlh1+/-), a model for Lynch syndrome, and wild type (Mlh1+/+) as a control 
were selected beacuse MLH1 gene is the most mutated gene in human LS and MLH1 promoter 
can be easily hypermethylated in patients with Lynch sydrome and in general population. (III)
Here specific aims were: 
2. To define the effects of Western diet on protein expression in histologically normal colon 
mucosa of wild type (Mlh1+/+) and Mlh1+/- mice (III)
3. To use network analysis and data mining to determine which of the affected proteins may 
be putative players in early CRC development (III)
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MATERIALS AND METHODS 
MSH2 VARIANTS (I-II)
This study included eighteen non-truncating mutations in MSH2 with the following ami-
no acid (AA) substitutions: c.97A>C à p.T33P, c.380A>G à p.N127S, c.482T>A à p.
V161D, c.484G>A à p.G162R, c.490G>A à p.G164R, c.518T>C à p.L173P, c.560T>C à 
p.L187P, c.815C>T à p.A272V, c.965G>A à p.G322D, c.998G>A à p.C333Y, c.1807G>A 
à p.D603N, c.1906G>C à p.A636P, c.2021G>C à p.G674A, c.2090G>T à p.C697F, 
c.2245G>A à p.E749K, c.2500G>A à p.A834T, c.2768T>A à p.V923E and deletion 
c.2235_2240del à p.I745-I746del. They will be further discussed as amino acid substitution in 
the MSH2 and called protein variants. Fifteen of them were found in putative Lynch syndrome 
families and thus functional assessment of pathogenicity was of the utmost importance. The 
variants p.N127S and p.G322D were studied because they had been shown to have frequent 
occurrence in patients with CRC but their classification was contradictory in the literature. The 
variant p.G674A , which was reported as a Lynch syndrome germline mutation (Raedle et al., 
2001), was included especially because it was shown to affect the biochemically interesting 
domain, Walker A motif, in MSH2 and was also shown to inactivate MMR in mouse cells (Lin 
et al. 2004).
Table 3 shows the clinical background of MSH2 protein variants. Eleven of the described vari-
ants were associated with families fulfilling the Amsterdam criteria I or II (AC). Four were 
found in several families, of which some fulfilled and some not the AC. Two variants were 
found in families, who did not fulfill the AC. IHC analysis showed loss of the MSH2 protein in 
tumors associated with 11 different variants, variable expression associated with one variant, 
and retained expression associated with 3 variants. The MSI high phenotype was present in at 
least one tumor connected to all 15 variants. 
All the studied MSH2 variations were expressed to a similar level as wild type MSH2 indicating 
protein stability. All the variant proteins, except p.G674A (Table 3) displayed normal interac-
tion with MSH6. (Ollila et al., 2006).
Twelve variants (p.V161D, p.G162R, p.G164R, p.L173P, p.L187P, p.C333Y, p.D603N, 
p.A636P, p.G674A, p.C697F, p.I745-I746del and p.E749K,) showed complete loss of MMR 
function, p.T33P showed decreased repair efficiency, and 5 variants (p.N127S, p.A272V, 
p.G322D, p.A834T and p.V923E) had normal repair efficiency compared to wild type MSH2 
(Ollila et al., 2006) (Table 3).
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PROTEIN PRODUCTION AND PURIFICATION (I-II) 
MutSa production
Site-directed mutagenesis, production of baculovirus vectors and production of vectors for hu-
man cell expression were completed prior to this work and will not be thoroughly discussed 
here (Ollila et al., 2006). 
Viral amplification
Sf9 cells were seeded in 20 mL of complete Grace’s Insect Cell Culture Medium (Gibco). After 
addition of virus, cells were incubated at 27°C for 5 days. The cell suspensions were centri-
fuged at 1000 rpm for 10 min and supernatants with amplified viruses stored at 4°C in the dark.
Infection of the Sf9 cells for protein production
Sf9 cells were co-infected with equal amount of virus containing 6x His-tagged wild type (WT) 
MSH6 and wild type or mutated MSH2 to express heterodimeric MutSa protein complexes. The 
cells were incubated for 3 days at 27°C.
Protein extraction
Total protein extracts were extracted from infected cells in cold lysis buffer (25 mM HEPES pH 
8, 2 mM 2 - mercaptoethanol, 0.5 mM spermidine, 0.15 mM spermine, 0.5 mM phenylmethyl-
sulfonyl fluoride (PMSF) and 2x complete protease inhibitor mixture (Roche)). The cells were 
allowed to swell on ice for 20 min followed by addition of ice cold 100% glycerol and NaCl to 
a final concentration of 300mM. Suspensions were rotated at 4°C for 30 min and centrifuged at 
14 000 rpm, 4°C for one hour. Supernatants were aliquoted, snap frozen in liquid nitrogen and 
stored at -80°C.
Ni-NTA purification
Recombinant MutSa protein complexes were purified from the total protein extract of Sf9 cells. 
Some of the variants (p.T33P, p.A636P, p.E749K, p.A834T, and p.V923E) were already pu-
rified by fast protein liquid chromatography (FPLC) by other researchers in the group. Here, 
the rest of the variants (p.N127S, p.V161D, p.G162R, p.G164R, p.L173P, p.L187P, p.A272V, 
p.G322D, p.C333Y, p.D603N, p.G674A, p.C697F p.I745-I746del) and wild type MutSa were 
purified from the total protein content of Sf9 cells with nickel-nitrilotriacetic (Ni-NTA) agarose 
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matrix (QIAGEN). Ni-NTA is tetradentate-chelating adsorbent, which occupies four of the six 
ligand-binding sites in the co-ordination sphere of the nickel ion. Two ligand sites are free to 
bind polyhistidine in the C-terminus end of the recombinant protein. In order to obtain active 
protein, native purification conditions were used. Thus, MSH2 remains bound to 6xHis tagged 
MSH6, enabling the co-purification of the two proteins (Gradia, Acharya & Fishel, 1997). Ni-
NTA matrix was washed with PBS three times prior to incubation with proteins. The ratio of 
matrix and total protein extract was 1:10 and incubation was in constant rotation at +4°C for 2 
hours. Suspensions of Ni-NTA and total protein extract were loaded into 1,5mL polypropylene 
columns (QIAGEN) and washed with 1mL of wash buffer (25 mM HEPES, 300 mM NaCl, 20 
mM 1,3- diazole (imidazole), 1 μL/mL leupeptin, 1x complete EDTA free 25x, 0.5 mM PMSF) 
six times. Recombinant proteins were eluted with increasing concentrations of imidazole in 
wash buffer. Certain mutated MutSa proteins were expressed in notably weaker concentrations 
compared to WT. Those were purified with a slightly modified protocol. The ratio of matrix 
and total protein extract was 1:20 and 20mM imidazole was added already prior to incubation. 
Furthermore, Ni-NTA agarose was washed with PBS containing 20 mM imidazole three times. 
The eluted proteins were dialyzed, aliquoted, snap frozen with liquid nitrogen and stored at 
-80°C. The concentration of proteins was determined after purification with the Bradford assay 
and by comparing the band intensities in SDS-PAGE gels stained with coomassie brilliant blue.
BANDSHIFT ASSAY (I-II)
Construction of labeled homo- and heteroduplex oligomers
To produce DNA substrates for bandshift assays, single-stranded 38mer oligomers (5’-TTTCT-
GACTTGGATACCATCTATCTATCTATAAAATAT-3’, the site of the putative mismatch in 
bold) were 5’ labeled with 32-phosphorus (32P). The kinase reaction was performed in a total 
volume of 10 μL containing 10 pmol of oligomer, 1x polynucleotide kinase (PNK) buffer (New 
England Biolabs), 100 mM DL-dithiothreitol (DTT), 10 pmol of 32- P-γ-ATP (Amersham), 
and 15 units of polynucleotide kinase (PNK) (New England Biolabs). The reaction was incu-
bated at 35°C for 45 min, followed by addition of 10 units of PNK and incubated at 35°C for 
30 min. Labeled oligomers were purified using ProbeQuant G-50 Micro Columns (Amersham) 
according to the protocol given by the manufacturer. To obtain double-stranded oligomers, 
the labeled single-stranded oligomers were annealed with 38 base-long complementary sin-
gle-stranded oligomers. The mixture of both oligomers (labeled and non-labeled) in a 1:1 ratio 
was denaturated at 95°C for 5 min and annealed at 37°C for 5 min followed by incubation at 
room temperature for 30 min.
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Mismatch binding and release assays
The bandshift assay was used to study the capability of recombinant MutSa proteins to bind to 
DNA heteroduplex-containing G●T mismatch, homoduplex-containing A●T, and to determine 
their ability to dissociate from DNA by ATP uptake.
The bandshift assay reaction mixture contained 10% glycerol, 100 mM KCl, 25 mM HEPES-
KOH pH 7.5, 1 mM DTT, 0.5 mM MgCl2, 0.1 mM adenosine diphosphate (ADP), 75 ng/mL 
bovine serum albumin (BSA), 60 ng poly-d(I-C), 25 fmol labeled oligomers and MutSa (350 
ng) in a total volume of 20 μL. The salt (NaCl) and HEPES concentration was adjusted to be 
similar in all samples. The reaction mixtures were incubated at 37°C for 20 min and 10μL of 
each mixture was separated into 5% acrylamide gels.
For ATP mediated release, 1μL of ATP in the desired concentration was added into the reaction 
after 10 min to obtain end concentrations of 0.5 mM, 1 mM and 2 mM, respectively. All gels 
were dried and visualized with phosphorimager Fuji and analyzed with TINA software version 
2.08e (Isotopen - meßgeräte GmbH).
MOUSE MODELS AND DIETS (III)
Heterozygote B6.129-Mlh1tm1Rak mice (Mlh1+/-) (strain 01XA2) (Edelmann et al., 1996) were 
obtained from NCI-MMHCC; National Institutes of Health, Mouse Repository, NCI-Frederick, 
MD. Mlh1+/- mouse has a deletion of exon 2 in one of the two of the Mlh1 alleles leading to a 
50% decrease of MLH1 protein. Instead of the exon 2 sequence it contains a box element with 
a stop codon. 
Diets 
American Institute for Nutrition (AIN) control diet (AIN-93G) is a semi-synthetic diet designed 
to meet the nutritional requirements of growing rodents (Reeves, Nielsen & Fahey, 1993), while 
Western style diet (WD*) is a modified AIN diet, which contains high dietary fat (39% of total 
calories while 17.2% in AIN-93G) and reduced contents of fiber, calcium, vitamin D, and three 
methyl-transfer donors (i.e. folic acid, methionine, and choline). Calories from carbohydrates in 
WD* are reduced for 20% in comparison to AIN-93G, nevertheless WD* has increased sucrose 
and correspondingly less complex carbohydrates than the control diet. Previously published 
Western diet differs from WD* in fat source, since Newmark et al. used corn oil (20%) (New-
mark et al., 2001), whereas WD* consists of milk fat (13.3%), canola oil (5.5%) and sunflower 
oil (1.2%) of the total 20% fat content. The fat source in AIN-93G is exclusively soybean oil 
(Table 4).
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Feeding experiment
Mice were bred and treated according to the 
study protocol approved by the National An-
imal Experiment Board in Finland (ESLH-
2008-06502/Ym-23). At the age of 5 - 6 
weeks (time point 0, tp0), Mlh1+/- and Mlh1+/+ 
mice were weaned from their mothers and 
randomly divided into two dietary groups. 
Mice were fed ad libitum with American In-
stitute for Nutrition (AIN-93G) control diet 
or WD* over 12 months and kept on a 12 h 
light/dark cycle with controlled temperature 
and humidity. Mice were weighted every 
two weeks by personnel at the Laboratory 
Animal Center, University of Helsinki.
Mice were sacrificed with carbon dioxide 
and sampled at tp0 (Mlh1+/- N = 8, Mlh1+/+ 
N = 7) and tp1 (12 months of age) (Mlh1+/+ 
AIN N = 8, Mlh1+/- AIN N = 6, Mlh1+/+ WD* 
N = 8, Mlh1+/- WD* N = 7). 
Histological studies 
Mice colons were examined under light microscope for possible neoplasias. All potential neo-
plasias were collected and analyzed at the Finnish Centre for Laboratory Animal Pathology 
(FCLAP), University of Helsinki, Finland. 
QUANTITATIVE ANALYSIS OF PROTEOMES (III)
Sample preparation from mouse colonic mucosa
For protein and mRNA studies, the colonic mucosa (10 - 25 mg) was separated from the un-
derlying submucosa and musculature under a dissecting microscope. Samples for protein ex-
tractions were rinsed with a solution of 10 mM Tris (Sigma-Aldrich, Finland) and 5mM mag-
nesium acetate (Sigma-Aldrich, Germany) (pH 8.5), snap frozen and stored at -80°C. Samples 
for RNA extraction were stored in RNAlater (Qiagen, Valencia, CA) at -80 °C.
Table 4. Composition of the diets
Compounds 
AIN-93G 
[g/kg]1
WD*  [g/
kg]1
Proteins [%] 20.3 23.5
casein 200 232
L-cysteine 3 3
Carbohydrates [%] 63 52
corn starch 397.49 305.63
maltodextrin 132 95
sucrose 100 116
Fat [%] 7 20
soybean oil 70 -
anhydrous milk fat - 132.82
canola oil - 55.42
sunflower oil - 11.82
cellulose 50 20
calcium 5 0.5
folic acid [mg/kg] 2 0.2
vitamin D [IU/kg] 1000 100
kcal from proteins [%] 18.8 18.5
kcal from carbohydrates [%] 63.9 42.3
kcal from fat [%] 17.2 39.2
1 if not stated differently 
2 Fat sources that differ in WD* from previously published 
Western diet (Newmark et al., 2001, Newmark et al., 2009) are 
in bold.
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Protein extraction from mucosa samples
Colonic mucosa samples were mechanically homogenized in the 2-D Protein Extraction Buf-
fer-VI (GE Healthcare) with addition of pH 8.5 Tris (30 mM) (Sigma-Aldrich) and Protease 
Inhibitor Mix (GE Healthcare) (1/100) (10-15 µL lysis buffer/mg tissue). After homogeniza-
tion samples were vigorously shaken for 20 min at 4 °C followed by centrifugation at 15 000 
g for 20 min. Supernatant was collected, snap frozen and stored at -80 °C. 2-D Quant Kit (GE 
Healthcare) was used to determine the protein concentrations of total extracts according to the 
manufacturer’s instructions.
2D Difference gel electrophoresis (DIGE)
All equipment and chemicals used in the proteomic study were from GE Healthcare if not 
stated differently. Proteomic changes were studied using the 2D DIGE method (Fig. 6). Half 
of the samples from each mouse group were labeled with 1-(5-carboxypentyl)-1′-propylindo-
carbocyanine halide N-hydrosuccinimidyl ester (Cy3) and the other four with 1-(5-carboxy-
pentyl)-1′-methylindodicarbocyanine halide N-hydroxysuccinimidyl ester (Cy5) (400 pmol of 
dye for 50 µg of sample) according to the manufacturer’s instructions. An internal standard 
was created by pooling 25 µg of each protein sample and labeling it with 3-[(4-carboxymethyl) 
phenylmethyl-3′-ethyloxacarbocyanine halide N-hydroxysuccinimidyl ester (Cy2). Isoelectric 
focusing was performed using 24 cm long immobilized pH 3-11 non-linear gradient (IPG) 
strips with the Ettan IPGphor II unit. The IPG strips were rehydrated for 8 hours in an IPG box 
using DeStreakTM reagent and IPG Buffer, pH 3-11 NL. An equal amount (50 µg) of internal 
standard labeled with Cy2 combined with Cy3 and Cy5 labeled samples was introduced active-
ly into the IPG strips using the cup-loading method according to the manufacturer’s recommen-
Fig. 6 Overview of the 2D-DIGE experiment. 
Samples are labeled with either Cy3 or Cy5. An 
internal standard, which contains equal amount 
of protein extract from all samples used in the 
experiment, is labeled with Cy2. Equal amounts 
of Cy3, Cy5 and Cy2 labeled protein extract are 
loaded into isoelectric focusing strips and pro-
teins are separated according to their isoelec-
tric point. Strips are transferred on top of large 
SDS-PAGE gels and proteins further separated 
according to their molecular weight. 2D protein 
spot maps from two samples (Cy3 and Cy5) and 
one internal standard (Cy2) are detected with-
in the same gel after scanning with a Typhoon 
scanner. DeCyder software is used for analysis 
of images, calculation of relative protein expres-
sions, as well as advanced analyses e.g. hierar-
chical clustering and principal component anal-
ysis.
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dations. Conditions of isoelectric focusing were: 21°C, 75mA/strip, Step1: step and hold: 150V, 
3h; step and hold: 300V, 3h; gradient: 1000V, 6h; gradient: 8000V, 1h 15min; step and hold: 
8000V, 3h 45min. Isoelectric focusing was followed by equilibration of IPG strips in two steps 
with 1% DTT and 2.5% iodoacetamide, dissolved in equilibration buffer containing 6 M urea, 
(Sigma-Aldrich), 2% SDS (Sigma-Aldrich), 50 mM Tris pH 8.8 (Sigma-Aldrich), 0.02% bro-
mophenol blue (Sigma-Aldrich) and 30% glycerol (Sigma-Aldrich) respectively. Separation of 
proteins in second dimension was carried out by transferring the equilibrated IPG strips to large 
12.5% SDS-PAGE gels and run in homemade Laemmli buffer with constant power of 15 W 
per gel until the bromophenol blue front reached the lower edge of the gel. Gels were scanned 
immediately after the run with Typhoon 9400 scanner. Cy2, Cy3 and Cy5 images were acquired 
with excitation/emission values 480/530 nm, 520/590 nm and 620/680 nm respectively, and 
maximum values between different channels were optimized to differ less than 20 - 30%. Gel 
images were analyzed using the software DeCyder 2D 7.0.
Protein identification 
The scanned gels were silver-stained using the PlusOne Silver staining kit (GE Healthcare). 
Selected protein spots were excised and proteins in-gel digested. Gel pieces were treated twice 
with acetonitrile (Sigma-Aldrich) (200 µL) and vacuum centrifuged until dry. Proteins were 
trypsinized (Trypsin gold; Promega, Sweden) and peptides were desalted using ZipTip (Milli-
pore, Germany), eluted and mixed with a-Cyano-4-hydroxycinnamic acid (CHCA) (Sigma-Al-
drich) on a MALDI plate. MALDI-MS and MALDI-MS/MS analyses were done with Autoflex 
III (Bruker Daltonics, Germany) using SmartBeamTM 355 nm laser. Calibration was externally 
performed with a peptide calibration standard (Bruker Daltonics). MALDI-MS spectra were 
acquired by accumulation of 5000 shots and MS/MS spectra 10000 shots. 
The MS and MS/MS spectra were searched against the UniProt/SwissProt database (taxon: 
Mus musculus, release of 2011_05; www.uniprot.org) using the Mascot server (Matrix Science, 
www.matrixscience.com) and FlexAnalysis and BioTools software (Bruker Daltonics). The fol-
lowing search parameters were implemented: cleaving enzyme trypsin, maximum one missed 
cleavage allowed, peptide mass tolerance ± 0.1 Da for MS searches and fragment tolerance ± 
0.5 – ± 1.5 Da for combined MS/MS searches. Oxidized methionine and carbamidomethylation 
of cysteine were set as variable and fixed modifications respectively.
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WESTERN BLOT ANALYSIS (I-III)
Expression levels of purified MutSa variants (I-II)
Expression levels of 6xHis tagged MSH6 together with counterpart MSH2 were analyzed by 
Western blot (6% SDS-PAGE), and compared with control protein samples with known con-
centrations. The primary antibodies used were MSH2 (ab-2) (Oncogene) (1:250) and MSH6 
(BD Bioscience Pharmingen), (1:1000) and the secondary antibody was anti a-mouse (Amer-
sham) (1:5000) coupled with horseradish peroxidase. The chemiluminescence reaction was 
visualized with X-ray film.
Expression levels of MLH1, SELENB1 and IDH1 in mouse samples (III)
The expressions of the proteins found to be important in 2D DIGE analyses such as MLH1, 
selenium binding protein 1 (SELENB1), and isocitrate dehydrogenase 1 (IDH1) were further 
studied with Western blot analyses. Forty µg of sample pools containing equal amounts of total 
protein extracts from each mouse belonging to a respective group (MLH1) or 15 µg of extract 
from each mouse in the group were used for the assay. Proteins were separated on 8% SDS-
PAGE for MLH1 and 14% for SELENBP1 and IDH1, blotted on Immobilon FL-PVDF (Mil-
lipore, MA, USA), and incubated with a primary antibody. The antibodies used were MLH1, 
clone G168-15 (1:500) (BD Pharmingen, San Diego, CA), SELENBP1, clone NBP1-54805 
(1:1000) (Novusbio, UK), and IDH1, clone #8137 (1:1000) (Cell Signaling Technology, MA, 
USA). The a-tubulin was used as a loading control (clone DM1A) (Sigma-Aldrich).
Two different detection systems were applied. For MLH1, the secondary antibody was the per-
oxidase labeled anti-mouse antibody (GE Healthcare) (1:20 000) and the blot was developed 
using ECL Prime Western Blotting Detection Reagents (GE Healthcare), detected with X-ray 
film. For SELENBP1 and IDH1, secondary antibodies were IRDye 800 CW goat anti-rabbit 
IgG (926-32211) (1:15 000) and IRDye 680 RD goat anti-mouse IgG (926-68070) (1:15 000) 
(LI-COR, Germany), respectively. The blots were scanned with Odyssey (LI-COR) and quan-
tified with the Image Studio Lite (LI-COR) software. Loading control (a-tubulin) was used to 
normalize protein abundance between WD* and AIN groups and additionally relative compar-
ison of the WD* to AIN group was performed for IDH1 and SELENBP1.  
RT-QPCR (III)
The RNA expressions were studied only for the genes that showed the most significant protein 
expression changes in 2D DIGE. The total RNA extracts were prepared using the RNeasyPlus 
Kit (Qiagen) with an extra DNAse treatment (Qiagen). The RNA integrity was analyzed with 
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Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA) and only high quality RNA (RNA integrity 
number RIN > 8) was used for cDNA synthesis reactions, 
which were run as duplicates and pooled for RT-qPCR re-
actions. Reverse transcription of pools of samples (200ng 
each) from 6 different mice belonging to the group Mlh1+/- 
AIN and 7 from Mlh1+/- WD* was achieved with Super-
script III (Life technologies, Carlsbad, CA), using ran-
dom primers according to the manufacturer’s instructions. 
(More details on RNA purification (Pussila et al., 2013).
The RT-qPCR analysis was done using TaqMan assays (Ta-
ble 5). Both pooled samples were assayed in triplicate for 
the target genes using the following cycling parameters: 
1 cycle of 95 °C for 10 min, 40 cycles of 95 °C for 15 s, 
and 60 °C for 1 min. Serine/threonine kinase 4 (Stk4) was 
used as an endogenous reference gene. Thermal cycling and fluorescence data acquisition were 
performed with the StepOnePlus cycler (Life Technologies) and Cq values were obtained using 
the Data-assist v2.0 software (Life Technologies). The mRNA expression changes in the Mlh1+/- 
WD* mice were analyzed using the comparative Ct (ΔΔCt) method, which presents the data as 
fold changes in gene expression normalized to the endogenous reference gene and compared to 
the expressions in the control group, Mlh1+/- AIN.
STATISTICAL ANALYSES (I-III)
Bandshift assays were repeated at least four times and all data were statistically analyzed in 
SPSS, version 12.0.1, using one-way ANOVA and tested with Tukey’s test with significance 
level 0.05.
The weight gains between the mouse groups were compared using the Student’s t-test and the 
Mann-Whitney U test (Lehmann & Romano, 2005). 
The protein spots with significant expression changes were detected using the DeCyder 2D 
Software 7.0 (GE Healthcare), and the expression means between the different mouse groups 
compared with the Student’s t-test.
The P value plot was created in the PASW Statistics 18 (SPSS Inc, IBM) using p values of all 
detected proteins obtained in t-test comparisons between the groups Mlh1+/- WD* and Mlh1+/+ 
AIN, Mlh1+/- WD* and Mlh1+/- AIN, Mlh1+/+ WD* and Mlh1+/+ AIN, and Mlh1+/- AIN and 
Table 5. TaqMan assays for 
studied genes
Gene Assay number
Acaa1b Mm00728805_s1
Acadm Mm01323360_g1
Aldob Mm00523293_m1
Atp5a1 Mm00431960_m1
Car1 Mm00486717_m1
Fabp2 Mm00433188_m1
Herpud1 Mm00445600_m1
Hspa5 Mm00517690_g1
Idh1 Mm00516030_m1
Pkm Mm00834102_gH
Slc2a1 Mm00441480_m1
Stk41 Mm00451755_m1
Taldo1 Mm00807080_g1
1Reference gene
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Mlh1+/+ AIN. P value plot reveals the number of expression changes with p value belonging to 
predefined bins and are represented with columns in the graph. Here we used: bin1: 0.05 ≥ p > 
0, bin2: 0.1 ≥ p > 0.05, bin3: 0.15 ≥ p > 0.1 with an increment of 0.05 until bin20: 1 ≥ p > 0.95. 
An increase of small p values (0.05 ≥ p > 0) will result in a skewed graph towards 0 showing an 
effect of a treatment, whereas an even distribution of p values will result in a flat graph indicat-
ing no significant effect of a treatment. 
The hierarchical clustering of mice was performed in the DeCyder extended data analysis using 
a set of proteins with significant expression changes by applying Pearson correlation and the 
average linkage method incorporated in the DeCyder software package.
The mean and median permutation tests (Efron et al., 2001) were used to analyze the expression 
data from RT-qPCR and Western blot and verify data from the 2D DIGE and. Pearson’s cor-
relation was used to analyze expressions obtained from 2D-DIGE and Western blot for selected 
proteins.
GENE ONTOLOGY AND NETWORK ANALYSIS (III)
Gene Ontology (GO) annotations were analyzed using the Panther Protein Classification Sys-
tem (http://www.pantherdb.org/) to distinguish significantly enriched functional annotations. 
The corresponding GO terms were used to assign protein functions. Network connections be-
tween human orthologs of differentially expressed mouse genes were studied using GeneMA-
NIA (www.genemania.org), which indexes 1464 association networks containing 292680904 
interactions mapped to 149747 genes from 7 organisms (last update 05/2013) (Warde-Farley 
et al., 2010). We further applied the GO biological process (GO BP) criteria for weighting 
of the networks and to maximize connectivity between all input genes into a given ontology 
class. Functional clustering of differentially expressed proteins in the Mlh1+/- WD* mice was 
achieved by combining protein interaction data and filtering it with medical subject heading 
terms (MeSH) with Human Integrated Protein-Protein Interaction rEference database, HIPPIE 
(http://cbdm.mdc-berlin.de/tools/hippie/information.php) (Schaefer et al., 2012, Schaefer et 
al., 2013) using medium confidence scoring (0.63). The following MesH terms in the neoplasm 
category were implemented for network analysis: neoplasms by site; neoplasms, hormone de-
pendent; neoplastic processes and precancerous conditions.
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RESULTS & DISCUSSION
BIOCHEMICAL ANALYSIS OF INHERITED MSH2 VARIATIONS (I-II)
Variants in the connector or lever domain cause protein degradation
To study biochemical defects of mutations in human MSH2 gene, we had transfected Sf9 cells 
and purified recombinant protein variants. All protein variants were expressed, although vara-
ints had broad difference between expression levels. Protein variants could be divided into two 
groups according to their expression level. MSH2 p.N127S, p.A272V, p.G322D, p. G674A were 
expressed similarly to MSH2 wild type and thus assessed as stable (Table 6, Fig. 1/I, Fig. 3/II). 
The rest of variants, except p.C697F, were expressed more than 10-fold less than MSH2 wild 
type. Of these, the MSH2 proteins p.V161D, p.G162R, p.G164R, p.L173P, p.L187P, p.C333Y, 
Table 6. The clinical and functional characteristics and interpretation of MSH2 variants
MSH2  
mutation Domain
Clinical 
data Functional data
1
Interpretation
AC2 MSI IHC3 Repair Stability Binding Release
T33P DNA binding - + + +(-) + + +(-) Inconclusive6
N127S4 Connector +/- + +/- + + + + Nonpathogenic
V161D Connector + + - - - NA NA Pathogenic
G162R Connector + + - - - NA NA Pathogenic
G164R Connector + NA - - - NA NA Pathogenic
L173P Connector + + - - - NA NA Pathogenic
L187P Connector + + - - - NA NA Pathogenic
A272V4 Connector +/- + + + + +(-) + Nonpathogenic
G322D4 Levers +/- +/- +/- + + + +(-) Nonpathogenic
C333Y Levers - NA NA - - NA NA Pathogenic
D603N4 Levers +/- +/- - - - NA NA Pathogenic
A636P ATPase + + - - + - NA Pathogenic
G674A ATPase NA NA NA - + +(-) - Pathogenic
C697F ATPase + + - - +(-) - NA Pathogenic
DEL745-746 ATPase + + - - - NA NA Pathogenic
E749K ATPase + + + - + + - Pathogenic
A834T5 ATPase + + - + + + + Nonpathogenic
V923E Helix-turn- helix + + - + + +(-) +(-) Inconclusive6
1 ‘-’ deficient, ‘+’ functional, ‘+(-)’ reduced
2 Fulfillment of Amsterdam criteria I or II: ‘-’ not fulfilled, ‘+’ fulfilled, ‘+/-’ status varies between families
3 Immunohistochemical analysis of MSH2 protein in a primary tumor: ‘-’ not expressed, ‘+’ expressed, ‘+/-’ expression status 
varies between reported cases
4 Mutations reported several times with different clinical characteristics
5 Another MSH2 mutation was found later and confirmed as the cause of cancer predisposition in this family
6 Variant is functional but shows reduced efficiency in one assay
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p.D603N and p.I745-I746del were highly degraded and seen as a ladder on a Western blot 
indicating high instability (Table 6, Fig. 2/II). The same protein variants were previously char-
acterized as pathogenic in the in vitro MMR assay (Ollila et al., 2006). These weakly expressed 
proteins, p.V161D, p.G162R, p.G164R, p.L173P, p.L187P, p., contained amino acid substitu-
tions in the connector domain, which plays a role in allosteric signaling between domains 3 and 
5 and has shown to be important for the stability of the MSH2 protein (Warren et al., 2007). A 
closer look at the amino acid (AA) substitutions revealed tremendous changes in (bio)chemical 
properties of AA residues. For example in p.V161D hydrophobic valine (V) is substituted into 
negatively charged aspartic acid (D), in p.G162R and p.G164R the smallest AA glycine (G) 
is substituted into positively charged arginine (R), and in p.L173P hydrophobic leucine (L) to 
proline (P), whose rigid structure affects the secondary structure of the protein. Any of these 
substitutions within the connector domain may explain decreased MSH2 stability and its low-
er expression level in human cells leading to MMR deficiency and cancer. Variants p.N127S 
and p.A272V are also within the connector domain but protein structure may not be affected 
since in both variants AA substitution is quite mild; in p.N127S substitution of asparagine (N) 
into serine (S) preserves similar polarity of the AA residue as well as in pA272V substitution 
of alanine (A) to valine (V). The variants p.C333Y and p.D603N were also weakly expressed. 
These substitutions are located in the lever domain of MSH2, which is responsible for signal 
transduction between the ATPase domain and the DNA binding domain (Warren et al., 2007). 
Structural changes in the lever domain can also explain MMR deficiency and pathogenicity. 
In summary, non-conservative substitutions of amino acids, affecting polarity, charge or struc-
ture in connector and lever domains disrupts stability of the protein.
Variants in the ATPase domain impair DNA binding or ATP-mediated release of protein 
(I-II)
MSH2 variants p.A636P and p.C697F do not bind to a mismatch
Recombinant proteins were grouped into two groups according to the purification method, since 
different methods could have led to different purities and thus affect bandshift assay results. 
The first group was purified with FPLC and contained MSH2 wild type (WT), p.T33P, p.A636P, 
p.E749K, p.A834T and p.V923E, whereas the second group, MSH2 - WT, p.N127S, p.V161D, 
p.G162R, p.G164R, p.L173P, p.L187P, p.A272V, p.G322D, p.C333Y, p.D603N, p.G674A, 
p.C697F and p.I745-I746del was purified with the Ni-NTA method. Ni-NTA method was used 
for proteins that were not sucessfully purified with FPLC. The recombinant MSH2 proteins 
p.V161D, p.G162R, p.G164R, p.L173P, p.L187P, p.C333Y, p.D603N and p.I745-I746del were 
not stable enough to obtain sufficient protein for the bandshift assay.
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Results are presented as percentages of MutSa-bound oligomers out of total amount of the 
labeled DNA. Oligomers without mismatch containing A●T were used as the control for un-
specific binding. Specific binding efficiency of purified MutSa variants for G●T was compared 
with binding of the wild type MutSa. FPLC purified MutSa - WT bound to the G●T oligomers 
with a higher efficiency (31.6 ± 12.2%) than the Ni-NTA purified WT (17.8 ± 7.6%). The re-
combinant proteins p.T33P, p.N127S, p.A272V, p.G322D, p.G674A, p.E749K and p.A834T 
bound to the labeled oligomers with G●T mismatch with similar efficiencies as the WT (Fig. 
2/I, Fig. 6/II). Statistically significant reduction in mismatch binding was detected for p.V923E 
(15.7 ± 6.1%, p < 0.01), p.A636P (2.3 ± 0.5%, p < 0.01) and p.G697F (1.8 ± 0.4%, p < 0.01) 
(Fig. 6/II). The MSH2 variant p.A636P is frequently found in Ashkenazi Jews and reported to 
predispose to CRC (Guillem et al., 2003). According to our study, p.A636P and p.C697F, both 
variants within the ATPase domain, cause MMR deficiency because they do not bind to DNA 
and support the already reported clinical phenotype for variant p.A636P in Ashkenazi Jews 
(Guillem et al., 2003). The MSH2 variant p.V923E also showed reduced, but still obtainable, 
binding to the heteroduplex.
MSH2 variants p.G674A and p.E749K impair release from a mismatch
All the protein variants, which were able to bind to the G●T mismatch (p.T33P, p.N127S, 
p.A272V, p.G322D, p.G674A, p.E749K, p.A834T and p.V923E) were further studied for their 
ability to release mismatch in the presence of ATP. Binding efficiency is presented as the per-
centage of the maximum amount of protein-bound DNA measured in a reaction without any 
ATP.
In the presence of 0.5 mM ATP, the binding efficiencies of MutSa - WT purified with Ni-NTA 
and FPLC were 12.9 ± 6.8% and 12.4 ± 6.2%, respectively. With the higher ATP concentrations 
the binding efficiencies of both MutSa purified with Ni-NTA and FPLC were reduced (for 1 
mM ATP 7.2 ± 3.2% and 6.1 ± 2.9% and for 2mM ATP 7.1 ± 4.3% and 5.0 ± 3.0%, respective-
ly). All other recombinant proteins, except p.G674A and p.E749K, released labeled oligomers 
after addition of 0.5 mM ATP. No significant differences between binding efficiency in samples 
after addition of 1 mM or 2 mM ATP were detected. With three different ATP concentrations 
p.G674A showed lower DNA release than WT protein (0.5 mM: 65.5 ± 21.8%, p<0.001; 1 mM: 
47.0 ± 19.5%, p < 0.001; 2 mM: 33.6 ± 23.1%, p < 0.01). Also p.E749K displayed reduced re-
lease from DNA in reactions with 1mM (21.2 ± 15.0%, p < 0.05 ) and 2mM ATP  (21.1 ± 16.3%, 
p < 0.05). The results are presented in Fig. 7/II.
The protein variants p.G674A and p.E749K have amino acid (AA) substitutions in highly con-
served motifs of the ATPase domain, which is responsible for the ATPase activity of MutSa. 
Substitution p.G674A is located in the Walker A motif (Fig. 7 A, B) and previous studies have 
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shown that variants in this motif affect MMR 
efficiency (Iaccarino et al., 1998). Moreover, 
p.G674A has been shown to affect protein 
ability to signal DNA damage and apopto-
sis (Lin et al., 2004). According to our re-
sults, the variant was normally expressed but 
MMR deficient. It was able to bind to hetero-
duplex DNA, but in the presence of ATP did 
not release normally from DNA, preventing 
downstream MMR proteins to proceed with 
repair. Our study thus shows that only one 
methyl group instead of hydrogen in the AA 
residue (G à A) can seriously impair pro-
tein function.
The MSH2 p.E749K variant, which also 
shows problems with mismatch release, is 
located in another conserved motif, Walk-
er B (Fig. 7 B, C). The corresponding mu-
tation in bacteria (Lamers, Winterwerp & 
Sixma, 2003) and Saccharomyces cerevisiae 
(Studamire et al., 1999) resulted in a high 
expression of a mutator phenotype. Our re-
sults suggest that this variant recognizes 
and binds to heteroduplex DNA, remaining 
bound to DNA in the presence of ATP, which 
Fig. 7 Variants MSH2 p.G674A in Walker A and 
MSH2 p.E749K in Walker B containing a mol-
ecule of ATP. A Variant p.G674A - substitution 
of glycine to alanine is close to the ATP binding 
site, which confirms the results that protein vari-
ant p.G674A releases less DNA in the presence 
of ATP. B Location of both variants p.G674A and 
p.E749K C Variant p.E749K in the Walker B mo-
tif is in the vicinity of the Mg2+ ion, and ATP. Mg2+ 
is necessary for normal MMR activity (Iaccarino 
et al. 2000) and it is possible that this protein 
variant affects Mg2+ binding. Glutamate has a 
negative charge, which stabilizes Mg2+ unlike 
lysine, which is positively charged. α - helix is 
in green, β - sheets in gold, red arrows and yel-
low – red stripes show amino acid substitutions. 
Cn3D software (NCBI) was used for 3D visual-
ization of the protein.
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disables downstream functions in MMR. Generally pathogenic MSH2 mutations causes the loss 
of MSH2 in the Lynch syndrome tumor (no staining detected in IHC). In a mutation carrier of 
p.E749K the protein was, however, present in tumor tissue (Mangold et al., 2005, Ollila et al., 
2006) indicating that the positive MSH2 staining in IHC is not always enough for exclusion of 
the MMR defect.
Inconclusive MSH2 variants 
The MSH variant p.V923E was expressed similarly to the WT protein and its repair efficiency 
in the in vitro MMR assay was similar to WT (Ollila et al., 2006). According to Sorting Intoler-
ant From Tolerant (SIFT) software this variant was predicted to be tolerated (Ollila et al., 2006). 
In our study, the variant bound normally to mismatch, but in the presence of ATP, released from 
it with a slightly lower efficiency; it was not significant. The colon cancer patient carrying this 
mutation and who also carries the mutation in MSH6 (protein variant p.S1188N) developed 
cancer at a later age of onset (70 y). It is likely that the p.V923E variant has just a mild patho-
genic effect and only together with another variation causes cancer.
The MSH2 variant p.T33P, which is located in the DNA binding domain of MSH2 showed 
decreased repair efficiency in the in vitro MMR assay, but was still functional (Ollila et al., 
2006) (Tables 3 and 6). The binding of p.T33P to heteroduplex DNA and ATP-mediated release 
from it was as efficient as WT´s. (Fig. 6 B & Fig. 7 B/II). This variant did not show problems 
in binding or release capabilities. Nevertheless, the fact that patient had an early endometrial 
cancer, and substitution of amino acid, from polar threonine to rigid proline, suggest deficient 
MMR kinetics.
Nonpathogenic MSH2 variants
The MSH2 variants p.N127S, p.A272V, p.G322D and p.A834T were stable, MMR proficient 
(Ollila et al., 2006), and as efficient in DNA binding and ATP-mediated release as the wild 
type protein. MSH2 p.N127S, p.G322D and p.A834T have been reported both in healthy pop-
ulations and in CRC patients, providing contradictory interpretations of their pathogenicity. 
Moreover, many carriers have been found to also carry another MMR gene variant (Table 1/I) 
(Froggatt et al., 1996, Fidalgo et al., 2000, Chadwick et al., 2001, Samowitz et al., 2001, Cravo 
et al., 2002, Chen-Shtoyerman et al., 2003, Lee et al., 2005, Tanyi et al., 2006). Although our 
results suggest that these variants do not cause MMR deficiency, we cannot exclude low pene-
trance effects, and connect these variants with low cancer risk.
Overall, our results classified 12 out of 18 variants as pathogenic, 4 as non-pathogenic and 2 we 
were not able to classify (inconclusive) (p.44 Table 6). 
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PROTEOMIC ANALYSIS OF THE EFFECTS OF DIET ON CRC DEVELOPMENT 
(III)
The lifetime risk for CRC in MMR gene mutation carriers can be as high as 80%, but disease 
phenotypes such as age of onset and tumor spectrum vary considerably between mutation car-
riers (Lindor et al., 2008) suggesting that environmental factors are involved in carcinogenesis 
also in the CRC syndrome. Westernized dietary habits in particular have been recognized as a 
high risk involved in CRC tumorigenesis explaining 50 - 80% of CRCs (Nystrom & Mutanen, 
2009). Diet does not necessarily generate mutations in DNA sequence as carcinogenic sub-
stances do, but most probably induces expression changes in key regulatory genes affecting 
normal metabolic processes in a cell. 
Mice fed with Western diet show increased weight gain and trend in development of neo-
plasias
Western diet has previously been associated 
with obesity (Fung et al., 2001); therefore in 
this study we followed weight gains of the 
mice in different diet groups. The weight 
gain is defined as increase in weights be-
tween tp0 and tp1. The average end weights 
in groups Mlh1+/+ AIN (N = 8), Mlh1+/- AIN 
(N = 6), Mlh1+/+ WD* (N = 8 ) and Mlh1+/- 
WD*  (N = 7) were 26.75 g, 29.67 g, 41.13 
g,  and 40.86 g, respectively. The average 
weight gain of the experimental groups in-
dicate no genotype effect on weight gain 
(Fig. 8). Therefore, the average weight gain 
in mice fed with WD* and AIN was 26.97 
± 7.77 g and 15.13 ± 4.85 g, respectively, 
indicating a significant diet effect on weight 
gain (p = 0.00005).  
Furthermore, macroscopic findings in colons 
of 29 mice at tp1 were five adenomas/hyper-
plastic polyps and one proximal adenocarci-
noma (Table 7, Fig. 9 modified from Pussila 
et al., 2013). Mice fed with WD* developed 
a substantial number of neoplasias, which 
Fig. 8 Average weight gains of different mouse 
groups. The mice fed with WD* (both genotypes 
Mlh1+/+ and Mlh1+/-) show increased weight gain in 
comparison to the mice fed with AIN, whereas ge-
netic background does not affect weight gain. * sig-
nificant difference between the groups; error bars 
represent SD.
Table 7. Type of neoplasms in mice  
Neoplasms
Mlh1+/- 
WD*
Mlh1+/- 
AIN
Mlh1+/+ 
WD*
Mlh1+/+ 
AIN
Hyperplastic 
polyp
1 1 0 0
Adenoma 2 0 1 0
Adenocarcino-
ma
0 0 1 0
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highlights the significance of WD* effect 
on CRC risk. The single AIN fed mouse 
that developed neoplasm (hyperplastic pol-
yp) was a mutation carrier. Previous studies 
on Western-style diet effects on CRC risk 
exposed WD as an inducer of benign and 
malignant colonic neoplasias also in wild 
type mice without inherited predisposition 
or carcinogenic treatments (Newmark et al., 
2001, Newmark et al., 2009). Although in 
that study mice were 18 months old while 
in our study only 12 months old, the only 
difference between the diets was that WD* 
contained a substantial amount of animal fat. 
Newmark & colleagues used vegetable fat, 
suggesting that animal fat may have acceler-
ated tumorigenesis.
According to Knudson’s two hit hypothesis 
(Knudson, 1971, Berger, Knudson & Pan-
dolfi, 2011) hereditary cancers occur only 
after the second hit in the tumor suppressor 
gene. To clarify whether the second hit al-
ready occurred during the feeding experiment in the Mlh1+/- mice we analyzed the expression 
of the Mlh1 gene in normal mucosa. Western blot analysis showed that Mlh1 was still well ex-
pressed in all mice groups demonstrating that MMR deficiency was not yet detectable in colon 
mucosa (Fig. 10). 
Differences in protein expression were mainly found between the Mlh1+/-  WD* and AIN 
mice
In proteomic analysis we found 394 protein spots with differentially changed expression due 
to aging, diet and aging and diet itself. However, twelve months old Mlh1 mutation carriers 
fed with WD* expressed the most significant expression differences when compared to mice 
fed with AIN control diet. The homozygote Mlh1+/+ mice did not generally show such a strong 
difference between the diet groups, as can be seen in the p-values of all the detected expression 
changes, which spread uniformly between 0 and 1 when Mlh1+/+ diet groups were compared to 
each other. On the contrary, the comparison between Mlh1+/- WD* mice and the AIN groups 
showed the highest number of significant p-values (Fig. 1/III).
Fig. 9 Histological image of a colonic adenocarcino-
ma, which was found in the Mlh1+/+ mouse fed with 
WD* (modified from Pussila et al. 2013).
Fig. 10 The expression of the MLH1 protein ana-
lyzed with Western blot. The heterozygote Mlh1+/- 
mice express approximately half of the amount of 
MLH1 expressed in their wild type littermates, be-
fore and after the feeding experiment.
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Despite insignificant protein expression changes between diet groups in Mlh1+/+ mice, expres-
sions showed often the same trends in the wild type Mlh1+/+ and the genetically predisposed 
Mlh1+/- mice, which can be seen by similar expression patterns in hierarchical clustering (Fig. 
2B/III). However, the most significant protein expression differences were mainly found be-
tween the Mlh1+/- WD* and the AIN groups. Moreover, after 12 months feeding, the Mlh1+/- 
mice clearly segregated into two different expression clusters according to the consumed diet 
(Fig. 2A/III), while the Mlh1+/+ mice showed a heterogeneous clustering. 
Western diet affects proteins involved in energy metabolism and cellular toxicity
The statistically significant differential abundances of protein spots at tp1 were mainly found 
between the Mlh1+/- WD* and the two AIN groups, thus the proteins for identification were 
selected exclusively from those comparisons. Altogether, 18 out of the 25 selected proteins 
were successfully identified by peptide mass fingerprint (Table 8, Fig. 11). Eleven proteins 
(ACADM, ALDOB, ATP5A1, CAR1, FABP2, IDH1, KRT19, LGALS4, SELENBP1, TAL-
Fig. 11 The image of a representative 2D gel with positions of 18 identified proteins (indicated by arrows) 
and named according to UniProt ID.
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Table 8. T
he 18 proteins show
ing statistically signifi
cant expression differences betw
een the M
lh1
+
/- W
D
* and the tw
o A
IN
 groups
Spot 
N
o.
U
niProt ID
N
C
B
I 
G
ene ID
N
C
B
I G
ene 
Sym
bol
U
niProt Protein N
am
e
Enzym
e
M
lh1
+/- W
D
* / M
lh1
+/- A
IN
 
M
lh1
+/- W
D
* / M
lh1
+/+ A
IN
Average 
ratio
T-test
perm
utation test
Average 
ratio
T-test
perm
utation test
m
ean
m
edian
m
ean
m
edian
1
P
13634
12346
C
A
R
1
C
arbonic anhydrase 1
4.2.1.1
1.94
0.015
0.08
0.116
1.64
0.022
0.023
0.048
2
P
17563
20341
S
E
LE
N
B
P
1
S
elenium
 binding protein 1
1.55
0
0.019
0.047
1.26
0.044
0.049
0.05
3
P
55050
14079
FA
B
P
2
Fatty acid-binding protein, 
intestinal 
1.48
0.008
0.009
0.024
1.29
0.017
0.018
0.024
4
P
45952
11364
A
C
A
D
M
M
edium
-chain specific 
acyl-C
oA dehydrogenase,           
m
itochondrial
1.3.99.3
1.24
0.004
0.01
0
1.17
0.02
0.02
0
5
Q
91Y
97
230163
A
LD
O
B
Fructose-bisphosphate         
aldolase B
 
4.1.2.13
1.19
0.014
0.006
0.008
1.14
0.075
0.078
0.06
6
O
88844
15926
ID
H
1
Isocitrate dehydrogenase 
[N
A
D
P
] cytoplasm
ic
1.1.1.42
1.18
0.001
0.003
0
1.12
0.012
0.011
0
7
Q
8K
419
16855
LG
A
LS
4
G
alectin-4 (Lactose-binding 
lectin 4)
1.17
0.019
0.041
0.032
1.05
0.42
0.416
0.523
8
Q
93092
21351
TA
LD
O
1
Transaldolase
2.2.1.2
1.16
0.015
0.024
0.019
1.1
0.056
0.057
0.193
9
Q
03265
11946
ATP
5A
1
ATP
 synthase subunit alpha, 
m
itochondrial
1.14
0.005
0.003
0.026
1.07
0.047
0.051
0.014
10
P
19001
16669
K
R
T19
K
eratin, type I cytoskeletal 19
1.13
0.011
0.014
0.003
1.06
0.063
0.059
0.134
11
P
40142
21881
TK
T
Transketolase
2.2.1.1
1.07
0.013
0.041
0.03
1.04
0.218
0.219
0.229
12
P
42932
12469
C
C
T8
T-com
plex protein 1 subunit 
theta
-1.09
0.002
0.003
0.003
-1.02
0.726
0.735
0.617
13
P
62259
22627
Y
W
H
A
E
14-3-3 protein epsilon
-1.09
0.014
0.026
0.03
-1.05
0.055
0.056
0.039
14
P
05784
16668
K
R
T18
K
eratin, type I cytoskeletal 18
-1.19
0
0.002
0
-1.16
0
0
0
15
P
52480
18746
P
K
M
2
P
yruvate kinase isozym
es 
M
1/M
2 
2.7.1.40
-1.3
0.016
0.025
0.052
-1.19
0.05
0.039
0.144
16
P
19324
12406
S
E
R
P
IN
H
1
S
erpin H
1
-1.33
0
0.01
0.014
-1.1
0.042
0.042
0.113
17
P
16045
16852
LG
A
LS
1
G
alectin-1
-1.33
0.001
0.028
0.011
-1.08
0.062
0.068
0.15
18
P
97315
13007
C
S
R
P
1
C
ysteine and glycine-rich 
protein 1
-1.59
0.005
0.008
0.023
-1.3
0.042
0.034
0.021
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DO1, TKT) showed an increased and 7 proteins (CCT8, CSRP1, KRT18, LGALS1, PKM2, 
SERPINH1, YWHAE) a decreased expression in the Mlh1+/- WD* group when compared to the 
AIN groups (Table 8). All the differences were significant when the Mlh1+/- WD* group was 
compared to the Mlh1+/- AIN group (fold changes vary between 1.94 and -1.53). The expres-
sions of ACADM, FABP2, IDH1, and KRT18 were also significantly changed when compared 
between the Mlh1+/- WD* and the Mlh1+/+AIN. All expressions used are calculated as percent-
ages and in comparisons between Mlh1+/- WD* and Mlh1+/- AIN mouse groups.
Gene ontology analysis of identified proteins expectedly associated 11 proteins with meta-
bolic processes (GO:0008152), whereas 6 proteins were associated with cellular processes 
(GO:00099987) (Fig. 5A/III). Panther database analysis divided the proteins into several differ-
ent classes, 4 proteins belonging to transferases (PC:002200), 3 to oxidoreductases (PC:00176), 
and 3 to lyases (PC:00144) (Fig. 5B/III).
Western diet disrupts cellular ROS homeostasis
Most expression changes associate with metabolic processes and neutralization of cell toxicity 
(Fig. 12). We detected the up-regulation of fatty acid-binding protein 2 (FABP2) in the Mlh1+/- 
WD* mice by 48% (p = 0.008), which most probably indicates a response to the high fat 
content of Western diet (20% in WD* vs. 7% in AIN). FABP2 is expressed exclusively in the 
intestine and its loss has been shown to cause assimilation of fatty acids in a cell (Agellon, Toth 
& Thomson, 2002). Free fatty acids are catabolized in fatty acid oxidation (FAO) that involves 
medium-chain specific acyl-CoA dehydrogenase (ACADM), which was increased by 24% (p 
= 0.004) in the Mlh1+/- WD* mice indicating a classical sign of starvation caused by decreased 
glucose levels (Klip et al., 1994, Tolwani et al., 2005) since the amount of carbohydrates in 
WD* was reduced by 20% (Table 4). Western style diet conditions cellular metabolism to uti-
lize fatty acids for their major energy source instead of glucose, which is usually done through 
the ketone body pathway. Additional verification studies on glucose uptake and fatty acid me-
tabolism showed increased mRNA expressions of solute carrier family 2 member 1 (Scl2a1 
known as Glut1) by 22% (p = 0) and (acetyl-Coenzyme A acyltransferase 1B) Acaa1b, involved 
in FAO of long chain fatty acids in peroxisomes, by 160% (p = 0). 
Up-regulated FAO and increased ATP synthase subunit a (ATP5A1) up to 14% (p = 0.005), 
which is part of OXPHOS, suggests an increase of reactive oxygen species (ROS) (Turrens, 
2003). Additionally, network analysis by GeneMANIA underlined ATP synthesis coupled pro-
ton transport (p = 7.05e-10, six proteins in the subnetwork including ATP5A1) (Fig. 6/III). 
Although the expression changes were detected in histologically normal colon mucosa even a 
moderate increase in ROS has been shown to damage proteins and DNA, regulate signaling, 
promote inflammation and eventually lead to cell death and cancer (Meng, Fukada & Tonks, 
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2002, Wu, 2006, Lu, Ogasawara & Huang, 2007, Veal, Day & Morgan, 2007, Lou et al., 2008, 
Trachootham, Alexandre & Huang, 2009, Hamanaka & Chandel, 2010, Levine & Puzio-Kuter, 
2010, Sena & Chandel, 2012). Furthermore, ROS levels are altered in many diseases (e.g. diabe-
tes, obesity, cancer) and attributed to pathology (Halliwell, 2007, Nathan, 2008, Trachootham, 
Alexandre & Huang, 2009).
The increased expression of Scl2a1, which has been reported to be increased not only because 
of low levels of glucose but also because of a high concentration of ROS (Bloch-Damti & 
Bashan, 2005), supports the elevation of ROS in the colon mucosa of the Mlh1+/- WD* mice. 
Neutralization of ROS by increased expression of enzymes that generate NADPH 
The cellular response to increased ROS levels is to neutralize their toxicity. In order to protect 
from ROS toxicity, enzymes involved in the production of NADPH are usually up-regulated 
(Matthews, Howarth & Butler, 2006, Kim et al., 2012). We detected two enzymes, transaldolase 
Fig. 12 Affected processes in normal colon mucosa of Mlh1+/- mice after mice were fed with WD* for 
twelve months. Western diet shifts energy metabolism towards fatty acid oxidation (FAO) and fatty acids 
become primary source of energy, which leads to upregulated oxidative phosphorylation (OXPHOS) and 
results in increased levels of reactive oxygen species (ROS). Increased levels of ROS damage proteins 
and DNA. Cellular mechanisms for reduction of ROS toxicity require nicotineamide adenine dinucleo-
tide phosphate (NADPH). Upregulated pentose phosphate pathway and reaction catalized by isocitrate 
dehydrogenase 1 produce NADPH, which is used for cellular defense of ROS. Damaged proteins may 
be degraded in process of ubiquitination, which may be mediated in selenium dependent manner by 
upregulated SELENBP1.
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(TALDO1) and transketolase (TKT), involved in NADP+ reduction in the pentose phosphate 
pathway (PPP), which were up-regulated by 16% (p = 0.015) and 7% (p = 0.013), respectively. 
Additionally, isocitrate dehydrogenase 1 (IDH1), which has recently been shown to function as 
a tumor suppressor gene (Parsons et al., 2008) and aids in total cellular production of NADPH 
for neutralization of ROS (Kim et al., 2012), was up-regulated in the Mlh1+/- WD* mice by 18% 
(p = 0.001). We confirmed expression of IDH1 with Western blot (35% higher expression (p 
= 0.035) in Mlh1+/- WD*), which highly correlated (R = 0.8137, p = 0.0042) with expression 
changes we detected in the 2D-DIGE experiment (Fig. 3/III). Furthermore, network analysis in 
GeneMANIA revealed the importance of the oxidoreduction coenzyme metabolic processes (p 
= 1.47e-4, four proteins including ALDOB, IDH1, TALDO1 and TKT) and the nicotinamide 
nucleotide metabolic processes (p = 9.77e-5, four proteins including ALDOB, IDH1, TALDO1 
and TKT) (Fig. 6 A, B/III) supporting our findings in proteomic analyses and underlining the 
Western diet insult on cellular ROS homeostasis.
mRNA expression of energy metabolism genes correlates with their protein expression 
Energy metabolism linked genes with highest expression differences were investigated at the 
mRNA level. The genes, Acadm, fructose-bisphosphate aldolase B (Aldob), Atp5a1, carbon-
ic anhydrase 1 (Car1), Fabp2, Idh1 and Taldo1 showed similar trends in expression changes 
at both the RNA and protein levels. The mRNA expression of Atp5a1 was not significantly 
changed between the diet groups and the pyruvate kinase isozyme M1/M2 (Pkm2), which was 
shown to have a significantly lower protein expression in the Mlh1+/- WD* group than in the 
AIN groups, was unexpectedly up-regulated at the mRNA level, suggesting that expression 
may be regulated at the protein level (Fig. 4 A-H/III).
Increased expression of SELENBP1 and LGALS4 – cellular response to neoplastic processes
Since statistically significant protein expression changes were mainly found in the heterozygote 
Mlh1+/- mice, we took further effort to look for functional connections between the 18 proteins 
and MLH1 using the HIPPIE database. 
In the HIPPIE network analysis, we stringently filtered protein interaction data with specific 
neoplastic MeSH terms. Analysis highlighted selenium binding protein 1 (SELENBP1) and 
galectin-4 (LGALS4) as important proteins in neoplastic/precancerous processes (Fig. 13). 
Both proteins directly interact with MLH1 and in the proteomic study showed an increase of 
55% (p = 0.000) and 17% (p = 0.019) in Mlh1+/- WD*, respectively. SELENBP1 was addi-
tionally studied in quantitative Western blot and showed higher expression (93% increase p = 
0.02). Moreover, Western blot expression highly correlated with expression changes we detect-
ed in 2D-DIGE experiment (R = 0.9013 p = 0.0004) (Fig. 3/III). The increased expression of 
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SELENBP1 has been previously reported in precursor lesions caused by chemical carcinogens 
(Scortegagna et al., 2009). SELENBP1 may also play a role in selenium-dependent ubiquiti-
nation/deubiquitination-mediated degradation of proteins (Jeong, Wang & Sytkowski, 2009) 
and have a tumor suppressor function inhibiting cell proliferation in the presence of ROS, such 
as H2O2 (Pohl et al., 2009). These findings support our hypothesis that here its expression is 
increased to help ubiquitination of proteins in the Mlh1+/- WD* mice and possibly prevent cell 
proliferation. The LGALS4 is a tumor suppressor gene known to down-regulate Wnt signaling 
target genes (Satelli et al., 2011). Thus, its increased expression also reflects a pre-tumorigene-
sis state where cells are trying to suppress pathogenesis. 
Additionally, the HIPPIE network analysis of the protein interaction data further linked ATP5A1 
directly to MLH1, while cysteine and glycine rich protein 1 (CSRP1), galectin-1 (LGALS1) 
and PKM2 were linked to MLH1 via bridging nodes.
Unfolded protein response may be disrupted in mice fed with Western diet
Serpin peptidase inhibitor clade H (SERPINH1, known as heat shock protein 47) associated 
with protein unfolding showed a 33% lower expression (p = 0.001) in the Mlh1+/- WD* group 
than in the Mlh1+/- AIN group, indicated possible changes in unfolded protein processes. 
In an attempt to confirm that the found expression changes really reflect the problems in un-
Fig. 13 The Hippie network analysis of the 18 differentially expressed proteins with the filter for neo-
plasms. MLH1 is directly linked to ATP5A1, LGALS4 and SELENBP1 and via bridging nodes to CSRP1, 
LGALS1 and PKM2 The medium confidence threshold (0.63 - second quartile in score distribution) was 
used for assigning the confidence of interactions.
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folded protein processes we decided to 
study unfolded protein response (UPR). 
Heat shock protein 5 (Hspa5, also known as 
Bip or Grp78) and homocysteine-inducible 
and endoplasmic reticulum stress-inducible 
ubiquitin-like domain member 1 (Herpud1) 
were selected for quantitative mRNA ex-
pression analysis as markers for UPR. UPR 
markers are actively transcribed, resulting in 
increase of mRNA amount, upon immediate 
stress related to unfolded proteins. Howev-
er, Hspa5 and Herpud1 showed 20% (p = 0) 
and 18% (p = 0) lower mRNA expressions 
in the Mlh1+/- WD* mice when compared to the Mlh1+/- AIN mice, respectively (Fig. 14). In a 
previous study on diabetic mice the decreased level of Hspa5 in older mice was suggested to 
associate with disrupted UPR and development of insulin resistance (Yamagishi et al., 2012), 
which may indicate that mice in our study developed insulin resistance or diabetes due to West-
ern diet. Along with emerging studies, which imply UPR as a cellular response on ROS induced 
oxidative stress (Cullinan & Diehl, 2006) linking ER stress to insulin resistance (Ozcan et al., 
2004) and that insulin-like growth factor (IGF-I) promotes tumorigenesis by stimulation of 
PI3K-Akt signaling (Gallagher & LeRoith, 2010, Weissman et al., 2012) our results shed light 
on this interesting field and underline need of further more specific mechanistic studies on this 
phenomenon.
Expression changes of detected proteins and CRC tumorigenesis
Many of the detected changes in protein expression (ACADM, ALDOB, ATP5A1, CAR1, 
LGALS1, LGALS4, and TKT) showed opposite expression trends than had previously been 
reported in colon cancer tissue (Barrow, Rhodes & Yu, 2011, Hu et al., 2011). However, the 
changes we found all occur prior to the second hit in the predisposed gene (Mlh1) and may be 
the most initiative alterations in a multistep tumorigenesis. Interestingly, if we take a broad 
view of detected changes in normal colon mucosa, they reflect the nutritional conditioning of 
colon mucosa and impose a mind-provoking thought as to whether normal cells can be clonally 
selected by nutritional insult to eventually become cancer cells. 
Fig. 14 The mRNA expressions of Herpud1 (A) and 
Hspa5 (B) in the different mouse groups. The fold 
changes of Mlh1+/- AIN and Mlh1+/- WD* were nor-
malized and compared to Mlh1+/- tp0. Data is pre-
sented as fold change mean ± SD (n = 3). * signifi-
cant difference between the groups.
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CONCLUSIONS
The study on biochemical defects of 18 MSH2 variants provided the following conclusions:
•	 Pathogenicity of studied variants associated with disruption of different biochemical 
mechanisms, which correlated with the functional domains of MSH2. 
•	 Variants in the ATPase domain did not affect expression of proteins or stability but ei-
ther reduced/abolished its mismatch binding or release capability.
•	 The 12 variants, which were shown to be pathogenic, also associated with the Lynch 
syndrome phenotype. The 6 variants with low penetrance were often indistinguishable 
from wild type protein, suggesting that in these families, other risk factors may contrib-
ute more than the inherited variation to cancer development.  
Quantitative analysis of Mlh1+/- and Mlh1+/+ mice colon proteomes after feeding experiment led 
us to conclude the following:
•	 Colon proteomes of the Mlh1+/- mice showed significant expression differences after 
feeding with two different diets, WD* and AIN-93G. 
•	 Network analysis underlined direct functional connections of the targeted proteins and 
implicated their up-regulation in early neoplastic processes.
•	 Western diet increases the amount of fatty acids, up-regulates fatty acid oxidation, ox-
idative phosphorylation, and thus also ROS, which is known to increase rate of DNA 
damage, supporting findings by Erdelyi et al. (Erdelyi et al., 2009). 
•	 	Many proteins, which are involved in neutralization of toxicity, were induced, support-
ing the idea that increase of ROS in histologically normal tissue may eventually lead to 
cancer development.
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FUTURE PROSPECTS
Biochemical characterization of MSH2 variants could be continued by studies on:
•	 Effects of mutations on MMR-mediated response to cytotoxic drugs
•	 Effects of mutations on MMR-mediated apoptotic signaling
•	 Effects of mutations on interactions between MutSa and MutLa complexes
The mouse diet study opened several interesting directions for future studies:
•	 UPR and ER stress linked to Western-style diet exposure should be studied in more 
detail and mechanically confirmed. 
•	 Results point towards disrupted metabolic pathways in colonocytes, therefore a metab-
olomic study would provide a mechanistic link between WD* and changes detected on 
the proteome level.
•	 Up-regulated fatty acid oxidation seen in the study increases the cellular pool of ace-
tyl-CoA, which affects cellular levels of acetylation modification processes. It would 
be interesting to access the genome wide status of histone acetylation and its possible 
association with oncogenic activation.
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Reason and logic, base of science, are pre-
dictable and reliable, but to understand se-
crets of nature many times we have to confide 
our emotions, intuition and gut feeling. 
Quite a few said to me that Acknowledge-
ments are the most interesting part of the 
doctoral dissertation. Probably because you 
finally get to feel person behind all that dry 
scientific writing. 
Keeping that in mind, I have to admit, I 
started to think about this very chapter way 
before I knew any line of the content of this 
dissertation, but left writing for a nice sum-
mer evening accompanied with few glasses 
of apple cider. Summer evening idea did 
not turn out to be that great because of all 
mosquitos, but that is charm of Finnish Sum-
mers, anyways. 
To live as a foreigner in Finland, one of the 
first questions you encounter is - Why Fin-
land? Honestly, I never gave any thoughts to 
Finland while living in Croatia. Only thing 
related to Finland was some story about Win-
ter War, and even that came back to my mind 
once I was already here in Finland, after 
hearing heroic stories of defeated Russians. 
Yes I knew that Helsinki is the capital, but 
lived ignorantly in belief that NOKIA is a 
Korean high-tech company. In all my igno-
rance I was suggested to apply for one, just 
started, exchange scholarship between Uni-
versity of Zagreb and University of Helsinki, 
and I got selected. Initially thought as four 
months scholarship, turned out to be almost 
a yearlong experience of Finland and later 
determined past five years of my life.
It is hard not to know at least one person 
closely related to any of us who hasn’t been 
affected by cancer. With two grandparents, 
both victims of different cancers I decided 
ZAHVALE
Razum i logika, osnovica znanosti, su pred-
vidljivi i pouzdani, no kako bismo razumjeli 
tajne prirode često moramo vjerovati emoci-
jama, intuciji i unutrašnjim osjećajima.
Mnogi su mi rekli kako su Zahvale najza-
nimljiviji dio doktorske dizertacije. Najvjero-
jatnije zato što konačno osjetiš osobu skrive-
nu iza suhog znanstvenog pisanja.
Moram priznati, imajući to na umu, počeo 
sam razmišljati o ovom poglavlju mnogo 
ranije nego što sam uopće znao sadržaj dis-
ertacije, no ostavio pisanje za jednu ljetnju 
večer uz nekoliko čaša jabukovače. Ideja 
o ljetnoj večeri u stvarnosti i nije bila baš 
sjajna zbog silnih komaraca, no to je ionako 
šarm finskih ljeta. 
Jedno od prvih pitanja na koja naletiš kao 
stranac u Finskoj je - Zašto Finska? Iskreno, 
dok sam živio u Hrvatskoj, nikada nisam 
razmišljao o Finskoj. Jedino što sam znao 
o Finskoj bilo je nešto o Zimskom ratu, a 
i toga sam se sjetio tek kad sam došao u 
Finsku, nakon što sam čuo herojske priče o 
poraženim Rusima. Istina, znao sam da je 
Helsinki glavni grad, no živio ignoratski u 
uvjerenju kako je NOKIA korejska high-tech 
kompanija. U svom tom svojem neznanju 
prijavio sam se na natječaj za tek uspostavl-
jenu bilateralnu razmjenu studenata između 
Sveučilišta u Helsinkiju i Sveučilišta u Za-
grebu i bio odabran. Prvotna četiri mjeseca 
razmjene pretvorila su se u gotovo godinu 
dana u Finskoj i predodredili proteklih pet 
godina mog života.  
Teško je ne znati barem jednu nam blisku 
osobu koja nije oboljela od raka. Činjenica 
da su i baka i djeda bili žrtve raka pobudila 
je moju želju da znanstvenu karijeru usmjer-
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to focus my scientific career in the field of 
cancer. Only person in Viikki at that time re-
searching cancer was Minna, very busy prin-
cipal investigator. By tactically approaching 
her PhD student, at that time, I got my way 
in the group for lab practice. Person, without 
who I would never end up doing research 
with Minna; my longest Finnish friend, 
great mind, the best lab companion and in 
moments of scientific lethargy the one to be 
there and give a kick - Saara - thank you for 
teaching me that I don’t know is not an an-
swer for a scientist, but let’s try to figure out, 
thank you for science we have shared. It is 
an honor to share publications with you. 
Small project in autumn 2006 led to Master’s 
thesis and already at that time Minna offered 
me possibility to go forward with doctoral 
studies. I was honored to be given that priv-
ilege and returned with enthusiasm in spring 
2009. That was official beginning of Minna’s 
and my scientific rollercoaster - an interest-
ing ride full of unexpected curves. Super-
vision is not an easy task, involves human 
beings and there is more to it than just sci-
entific mentoring. It is easy to troubleshoot a 
PCR, Western blot, but it takes a lot more to 
troubleshoot a person, and Minna has it. Es-
pecially, thank you for all scientific freedom.
Soon after I started with PhD, Saara left 
for a postdoc. Being only foreigner in the 
group, quite cocky for Finnish taste, rather 
straight-forwarded and opinionated with 
deep Southern Europe expressive mentality 
I wished for more international surrounding. 
Eventually, new student came to our group. 
It was around period when I started with 
proteomics and 2D DIGE optimizations in 
our lab. I had my hopes high when heard that 
she is half British half Finnish. She won me 
over with her straightforward personality, 
efficiency breaking the sky, reliability and 
responsibility in the lab performance, but I 
still don’t know what was the reason why she 
im u to područje. Jedina osoba u Viikki-ju 
koja je istraživala rak bila je Minna, vrlo 
zaposleni israživač. Uspio sam ući u njez-
inu grupu i odraditi praksu u laboratoriju 
tako što sam strategijski pristupio njezinom 
PhD studentu. Osoba bez koje nikada ne 
bih istraživao s Minnom; moj najduži finski 
prijatelj, izvrstan um, najbolji lab drug i ona 
koja u momentima znanstvene letargije zna 
kako me pomaknuti - Saara - hvala ti što si 
me naučila da ne znam nije odgovor jednog 
znanstvenika, nego hajmo pokušati pronaći 
odgovor, hvala za znanost koju smo dijelili. 
Čast je dijeliti publikacije s tobom. 
Mali projekt u jesen 2006 doveo je do dip-
lomskog rada i već u to vrijeme Minna je 
ponudila da nastavim s PhD studijem. Bio 
sam počašćen njezinom ponudom i vratio se 
pun entuzijazma u proljeće 2009. To je bio 
početak Minninog i mog zajedničkog roller 
coaster-a - interesantna vožnja puna iznenad-
nih krivina. Mentorstvo nije jednostavan za-
datak, uključuje ljudska bića i mnogo je više 
nego znanstveno usmjeravanje. Jednostavno 
je otklanjati PCR ili Western blot pogreške, 
no mnogo je teže usmjeravati osobu - Minna 
ima to u sebi. Posebno ti hvala na pruženoj 
znastvenoj slobodi.
Ubrzo, nakon što sam započeo s doktoratom, 
Saara je napustila grupu i započela s post-
doc-om. Kao jedini stranac u grupi, poprilič-
no nadmen za finski ukus, direktan i samouv-
jeren sa snažnim izražajnim južno-europskim 
mentalitetom želio sam međunarodno 
okruženje. Konačno smo dobili novu studen-
ticu. Bilo je to otprilike kada sam započeo 
s proteomikom i 2D DIGE optimizacijom. 
Moja očekivanja su bila velika kada sam 
doznao da je pola Britanka pola Finkinja. 
Osvojila me svojom direktnošću, učinkovito-
sti bez limita, pouzdanosti i odgovornosti u 
laboratoriju, no još uvijek ne znam što je bio 
razlog zašto je ona odabrala raditi svoj dip-
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chose to do her Master’s project with me, oc-
casionally mercurial personality. Long hours 
in the lab, so many optimizations, so many 
failures, but she was persistent together with 
me in casting numerous polyacrylamide gels. 
In these moments I tried to remember what 
I learned from Saara and give that back to 
Satu. I don’t know if I succeeded, but defi-
nitely you were an exceptional companion in 
the lab, and more importantly, stayed a great 
friend in my life.   
2D DIGE, an old proteomic method with 
a modernized twist, came to my life on a 
course of Basic Protein Chemistry and Pro-
teomics organized by Marc. I saw 2D gels 
and protein spots on them (Fig.10) as a night 
sky with stars, and that all these spots may 
lead biologists to uncharted discoveries as 
star constellations led explorers to new con-
tinents. Eventually I got opportunity to sail a 
boat on my own. Marc was always support-
ive and ready to troubleshoot problems. He 
was there with good mood, cheery attitude 
and new technologies to broaden scientific 
horizons - an important segment of PhD 
training. 
In the last year of my PhD life, I encountered 
rather frustrating periods, when you try to 
publish article and get subsequent rejections 
from journals - one person from Marc’s lab 
always found some time for my issues and 
frustrations, despite that in his job descrip-
tion is not included mentor a guy who is 
hanging around your MALDI. Many times 
his advices reminded me on my mum’s - 
Rabah - one big shokran! Many supervisors 
could take advices from you. 
Once you get list of proteins - how on Earth 
do you interpret that? You go one-by-one. 
Luckily, I had less than two dozen. Reading 
all articles and thinking about processes in 
which these proteins are involved, painting 
larger picture took significant amount of 
lomski sa mnom, koji sam ponekad nestalan 
poput žive. Dugi sati u laboratoriju, mnogo 
pokušaja optimizacije, mnogo neuspješnih 
eksperimenata, no ona je bila uporna zajedno 
sa mnom u izlijevanju nebrojenih poliakril-
amidnih gelova. U tim trenucima trudio sam 
se sjetit što sam naučio od Saare i prenijeti 
isto Satu. Ne znam jesam li uspio, no defin-
itivno si bila izuzetan kolega u laboratoriju, 
i još važnije, ostala veliki prijatelj u mom 
životu. 
Na 2D DIGE, koja je modernizirana stara 
proteomska metoda, sam naišao na kolegiju 
Osnove Proteinske Kemije i Proteomike u 
Marc-ovoj organizaciji. 2D gelovi i razdvoje-
ni proteini u obliku točaka (Slika 10) pods-
jećali su me na noćno nebo sa zvijezdama. 
Kako su nekoć sazvježđa navodila moreplo-
vce do novih kontinenata tako bi sve te točke 
mogle voditi biologe do novih otkrića. Kad 
sam dobio priliku zaploviti svojim brodom, 
Marc je bio pun podrške, spreman pomoći 
u otklanjanju problema i uvijek prisutan s 
dobrim raspoloženjem, živahnim nastupom i 
novim tehnologijama kako bi proširio znas-
tvene vidike - važan element PhDija.  
U zadnjoj godini PhDja, suočavao sam se 
s poprilično frustrirajućim periodima kada 
pokušavaš objaviti članak a časopisi uzasto-
pno šalju odbijenice. Jedna osoba iz Marc-
ovog laba je uvijek našla vremena za moje 
probleme i frustracije, usprkos tome što mu u 
opisu posla nije uključeno budi mentor osobi 
koja visi okolo MALDI uređaja. Često su 
me njegovi savjeti podsjetili na savjete moje 
mame - Rabah - jedno veliko hvala! Mnogi 
mentori bi se mogli ugledati na tebe.
Kada konačno dobiješ listu proteina - kako 
protumačiti rezultate? Kreneš jedan po jedan. 
Srećom sam ih imao oko dvadeset. Čitanje 
članaka, procesuiranje činjenica i pokušaji da 
se uspješno sve poveže u cjelinu uzeli su po-
prilično vremena. Kasnije me Maciej naučio 
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time. Later on, Maciej taught me how to, first 
sketch larger picture, and then add colors by 
network analysis – dziękuję. 
For past consecutive four years, sometime 
after Halloween, the period when Finland 
turns into Mordor I was assembling meet-
ings with Minna and two of my follow-up 
advisors, Pekka and Juha. Over coffee and 
cookies, we would discuss project and future 
steps. Your steering wes always appreciated. 
When we decided to establish 2D DIGE in 
our lab, apparent support came from head of 
Division of Genetics, Tapio. Thank you for 
lending me your equipment for 2D DIGE 
and supporting Minna in acquiring Typhoon 
scanner. 
Laura, Marjaana, Minttu, Jukka, Mariann 
thank you for sharing office and lab time 
with me. Arja Ikävalko and Outi, like two 
angels in the lab, always happy and with 
smile made work in the lab many times less 
stressed - kiitos. Karen thank you for effi-
cient and fast language check up.
I have to admit I traveled on many scientific 
conferences and most of them would not be 
possible without former Graduate Program in 
Biotechnology and Molecular Biology, Erkki 
and Anita, who both were always friendly 
and helpful.
Even though I really like working in the wet 
lab every now and then I need a break. In 
spring 2010 I came across problem based 
learning course CancerBio Summer School, 
which ended with Amazing Cancer Race 
event. An unusual, very interactive in its 
core, this course and its main organizer, Juha 
Klefström, have given me ever since the 
biggest teaching and organizing experience. 
An awesome and very creative course Juha, 
thank you for opportunity to be part of the 
team, grow teaching and organizing skills. 
kako prvo skicirati sliku, a potom dodati 
boje, koristeći analizu mreža - hvala ti.
Proteklih pet godina, negdje otprilike nakon 
Noći vještica, u vrijeme kada Finska postane 
Mordor ja bih sazvao sastanak s Minnom 
i svojim pratećim savjetnicima, Pekkom i 
Juhom. Uz kavu i kekse mi bi raspravili o 
projektu i budućim koracima. Vaši savjeti i 
usmjerenje uvijek su bili cijenjeni. 
Kada smo odlučili uspostaviti 2D DIGE u 
našem laboratoriju, velika je podrška došla 
od upravitelja odijela genetike, Tapia. Hvala 
ti što si dopustio korištenje 2D DIGE opreme 
i bio podrška Minni u nabavljanju Typhoon 
skenera. 
Laura, Marjaana, Minttu, Jukka, Mariann 
hvala vam na vremenu koje smo dijelili u 
uredu i laboratoriju. Arja Ikävalko i Outi, 
poput dva anđela u labu, mnogo puta ste svo-
jim veseljem učinile rad u laboratoriju manje 
stresnim - hvala. Karen hvala za učinkovitu i 
brzu provjeru engleskog jezika.
Moram priznati da sam putovao na mno-
go znanstvenih simpozija i većina ih ne bi 
bila moguća da nije bilo Poslijediplomskog 
Programa u Biotehnologiji i Molekularnoj 
Biologiji, Erkki-ja i Anite koji su oboje bili 
uvijek prijateljski i od pomoći. 
Iako volim raditi u laboratoriju, ponekad mi 
je potrebna stanka. U proljeće 2010 pronašao 
sam kolegij koji je baziran na problemskoj 
nastavi - CancerBio Ljetna Škola koja za-
vršava s Nevjerojatnom Rak Utrkom. Vrlo 
neobičan, interaktivan u srži, ovaj kolegij mi 
je zajedno sa svojim glavnim organizatorom, 
Juhom Klefström, pružio najveće iskust-
vo u nastavi i organizaciji. Izvrstan i vrlo 
kreativan kolegij Juha, hvala ti za pruženu 
mogućnost da budem dio tima i unaprijedim 
svoje vještine u nastavi i organizaciji.  
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I have had a partner in crime in organization 
of Amazing Cancer Race for past four years. 
A person who is my oldest friend in Finland, 
but not a Finn; a person with mentality closer 
to mine than any Northerner, but still North-
ern enough that we both like living here; a 
person with whom we shared many, many 
coffees in the early era of Helsinki coffee 
scene, when cafeterias were not that fine and 
stylish as they are now, but we both needed 
that table, coffee or tea and endless talks, 
sometimes about cancer, sometimes about 
philosophy; a person who dears to tell me the 
truth, even is aware that I’ll not take it lightly 
but knows that I appreciate direct word more 
than anything; a great listener, always there 
for me - Maral - با تشکر از شما
Plato based his soulmate theory on a myth 
that many, many thousands of years ago, 
humans were androgynous creatures, which 
were punished by Zeus and split into two – 
male and female humans. According to the 
theory all of us are seeking our other half. If 
anyone proves Plato’s theory, later revised by 
Schopenhauer and Jung, true that are Maral 
and Nima themselves. I am grateful of hav-
ing you guys as friends and honored of hav-
ing Nima as a co-author on a publication. It 
was pleasure to learn from you statistics, and 
it is always joy to share high quality discus-
sion with you. 
Process of making friendships is slow in 
Finland, but the most unusual beginning of 
a friendship was on HNPCC symposium in 
2010, when we spent the whole night drink-
ing and talking about cultural differences, 
high heels, Russian girls and other serious 
stuff. Since then these two extraordinary 
girls have been sincere friends, Eevi & Mer-
vi, thank you for many inspirational talks.
Another special friendship, which started 
on a bus station in Viikki in late Autumn 
enriched my life; talks with you cheered me 
Proteklih četiri godine imao sam partnera 
u zločinu za organizaciju Nevjerojatne Rak 
Utrke. Osoba koja je moj najstariji prijatelj u 
Finskoj, a nije Finkinja; osoba čiji je men-
talitet bliži mome nego mentalitet bilo kojeg 
Sjevernjaka, no juš uvijek dovoljno Sjeveran 
da oboje volimo živjeti ovdje; osoba s kojom 
sam dijelio mnogo kava u ranoj eri Helsinške 
kava scene kada kafeterije nisu bile tako 
stilski uređene kao što su sada, no nas oboje 
smo trebali taj stol, kavu ili čaj i beskra-
jne razgovore, nekad o tumorima, nekad o 
filozofiji; osoba koja se usudi reći mi istinu 
iako je svjesna da to neću lagano primiti, no 
zna da cijenim direknu riječ više od ičega; 
izvrstan slušatelj, uvijek tu za mene - Maral - 
mnogo ti hvala. 
Platon je bazirao svoju teoriju o srodnim 
dušama na mitu da su prije mnogo, mno-
go tisuća godina ljudi bili androgena bića 
koja je Zeus kaznio i razdvojio u dva spola 
- muškarca i ženu. Po toj teoriji svatko od 
nas traži svoju drugu polovicu. Ako je itko 
dokaz Platonove teorije o srodnim dušama, 
koju su kasnije obradili Schopenhauer i Jung, 
to su onda Maral i Nima. Zahvalan sam što 
vas imam za prijatelje i počašćen da je Nima 
ko-autor na mom članku. Bilo je zadvoljst-
vo učiti statistiku od tebe i uvijek je veselje 
dijeliti visoko kvalitetnu diskusiju s tobom. 
Proces stvaranja prijateljstva u Finskoj je 
spor, no najneobičniji početak prijateljstva 
dogodio se na HNPCC simpoziju 2010, kada 
smo proveli cijelu noć pričajući uz piće o 
kulturološkim razlikama, visokim petama, 
Ruskinjama i ostalim ozbiljnim temama. Od 
tada te dvije posebne curke su bile iskreni 
prijatelji, Eevi i Mervi hvala za mnogo inspi-
rativnih razgovora. 
Još jedno posebno prijateljstvo, koje je poče-
lo na busnoj stanici u Viikki-ju jednog jesen-
jeg dana, je obogatilo moj život, razgovori 
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up, thank you for support when I would feel 
down - Ave.
Back into 2007, after I finished lab in Min-
na’s group I stayed in Finland as a kesämies 
in Ecological Genetics Research Unit. Once 
I returned back to Croatia in 2008, they 
gave a really tempting deal to come back as 
a research scientist and stay later as a PhD 
student. I know that there is just one person 
to thank that for. We had a click. She was 
precise and demanding as a supervisor in the 
lab, sometimes cocky and pain in the ass :) 
but we had fun and more than anything for 
these short two months we became friends. 
When I came back to Finland we had our 
history. You experienced the best and the 
worst of me. I am grateful to have you Mari-
ka in my life. 
Marika brought into my life hairy 27 kg of 
unconditional love, as Marika used to call 
her. I am happy for given opportunity to 
share runs, walks and your moments of hap-
py, happy joy super fast after pooping runs 
- Iitu. When all humans failed, when world 
looked like falling apart, you were the one 
to push your head between my arms, come 
close and cheer me up.
Very few Croatians live in Finland, even less 
that studied the same faculty in Croatia, but 
I got lucky to share a full year with one of 
them. Finally I had our (Croatian) type of 
coffee breaks and chitchat in our language. 
It was an awesome year being able to speak 
Croatian and not care what people around 
would say, being able to go spontaneously 
for a glass of cider after work and end up in 
a bar until morning. Thank you for our trips, 
thank you for friendship, Jasna.  
When Jasna, who many times was like a 
bigger sister to me, moved back to Croatia 
two persons became very close to me, and 
very important in my life. With one I shared 
s tobom su me uvijek razveselili, hvala ti za 
potporu kada bih bio depresivan - Ave. 
Natrag u 2007, nakon što sam završio labo-
ratorij u Minninoj grupi ostao sam u Finskoj 
kao kesämies u Ekološko Genetičkoj Is-
traživačkoj Jedinici. Nakon što sam se vratio 
u Hrvatsku, u 2008 ponudili su mi vrlo pri-
mamljivu poziciju da se vratim kao istraživač 
i nastavim kao PhD student. Znam da je iza 
svega toga stajala samo jedna osoba. Mi 
smo imali klik. Kao supervizor u labu bila je 
ponekad trn u oku, nadmena, precizna, zaht-
jevna, no mi smo oboje uživali i u tih kratkih 
dva mjeseca postali prijatelji. Kada sam se 
vratio u Finsku imali smo svoju priču. Ti si 
iskusila najbolje i najgore u meni. Zahvalan 
sam što te imam u svom životu Marika
Marika je unijela u moj život dlakavih 27 kg 
bezuvjetne ljubavi, kako ju je Marika zvala. 
Sretan sam što imah priliku trčati i ići u šet-
nje s tobom i biti dio tvojih manično veselih 
trčanja nakon što bi se pokakala - Iitu. Kada 
bi me svi ljudi iznevjerili, kada je svijet 
izgledao kao da se raspada, ti bi gurnula 
svoju glavu između mojih ruku, došla blizu i 
razveselila me.
Malo Hrvata živi u Finskoj, a još manje 
onih koji su studirali na istom fakultetu u 
Hrvatskoj, no bio sam sretnik koji je proveo 
godinu dana s baš takvom osobom. Konačno 
sam imao naš (hrvatski) tip pauzi za kavu i 
čakule na našem jeziku. Bila je to zakon go-
dina kada smo pričali hrvatski ne obazirući 
se što će ljudi okolo reći, kada bismo sponta-
no otišli na jabukovaču poslije posla i ostali 
u baru do jutra. Hvala za naša putovanja, 
hvala za prijateljstvo, Jasna. 
Nakon što se Jasna, koja mi je bila mnogo 
puta kao velika sestra, vratila u Hrvatsku, 
postao sam vrlo blizak s dvije osobe i one su 
postale vrlo bitne u mom životu. S jednom 
66
ACKNOWLEDGEMENTS                                                                                                               Denis Đermadi Bebek
neighborhood, beers in the yard, many de-
licious dinners, some deep talks, but more 
than anything true friendship. Thank you 
Kukka. With another one I did not share 
neighborhood, but direct bus line. Number 
14 was main connection to many parties, gin 
& tonics and many more moments we’ve 
shared. Thank you for being there when I 
needed moments to relax, forget about work, 
talk about issues. Thank you Nina for taking 
care of my social life. Thank you for trance!
Life is a path with many crossings and each 
crossing represents a choice. Each choice 
imposes withholds. There are no words that 
would express my gratitude to this person 
who has chosen me over herself on each 
crossing; who has always made life situa-
tions look nicer so I wouldn’t worry; who 
has always overstrained herself so I wouldn’t 
feel heaviness of life; who has fought every 
life challenge alone and life took care that 
challenges are not lacking. Mum, without 
your support I woudn’t been here where I 
am. Without you I wouldn’t be what I am.   
At first I thought that South and North 
couldn’t be combined, but we have shared 
our lives for a bit more than two years, two 
very dynamic years consisting of a lot of 
traveling, many unforgettable parties, some 
tears, some laughs, days with rain, days with 
storms, mornings with rainbows… Even 
though you may not see, but you calmed and 
balanced me with your Scandinavian mental-
ity. Thank you for going through every single 
sentence in this thesis with me, questioning 
meaning, language and style. Thank you for 
staying even in the moments when I couldn’t 
stand myself, thank you for bringing the best 
in me - Joni. 
sam dijelio susjedstvo, piva u dvorištu, mno-
go ukusnih večera, poneked ozbiljne razgo-
vore no više od ičega istinsko prijateljstvo. 
Hvala Kukka. S drugom pak nisam dijelio 
susjedstvo, već direktnu bus liniju. Bus broj 
14 bio je glavna veza za mnogo partija, gin 
i tonike i mnogo više trenutaka koje smo 
dijelili. Hvala što si bila uvijek blizu kada 
sam trebao opuštanje, zaboraviti posao, 
razgovarati o problemima. Hvala Nina što 
si se brinula za moj socijalni život. Hvala za 
trans!
Život je put s mnogo raskrižja i svako 
raskrižje predstavlja izbor. Svaki izbor uv-
jetuje odricanja. Nema riječi kojima bih 
izrazio zahvalnost osobi koja je na svakom 
raskrižju odabirala mene umjesto sebe; osobi 
koja je uvijek uljepšavala životne situaci-
je kako se ja ne bih brinuo; osobi koja se 
uvijek prenapregnula u cilju da ne osjetim 
težinu života; osobi koja se borila sama sa 
svakim životnim izazovom, a život se uvijek 
pobrinuo da ih ne manjka. Mama, bez tvoje 
podrške nikada ne bih bio ovdje gdje jesam. 
Bez tebe ne bih bio to što jesam. 
U početku sam smatrao da jug i sjever ne 
mogu biti spojeni, no mi dijelimo naše živote 
malo više o dvije godine, dvije vrlo din-
amične godine ispunjene s mnogo putovanja, 
mnogo nezaboravnih tuluma, ponešto suza, 
ponešto smijeha, dvije godine ispunjene 
kišnim danima, olujnim danima i jutrima 
s dugama... Iako ti možda ne vidiš, no ti si 
me smirio i uravnotežio sa svojim skandina-
vskim mentalitetom. Hvala ti što si sa mnom 
prošao kroz svaku rečenicu ove disertacije, 
provjeravao smisao, jezik i stil. Hvala ti što 
si ostajao uz mene čak i u trenucima kada 
sam sebe nisam mogao izdržati, hvala ti što 
izvučeš najbolje iz mene - Joni. 
Denis
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